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SEARCH 
THE ROCKEFELLER UNIVERSITY MAGAZINE 
Special Feature: The Many Facets of 
AIDS Research at Rockefeller 
Twelve years after the start of the AIDS 
epidemic, the plague remains unconquered. 
Researchers at The Rockefeller University are 
among the thousands of scientists worldwide 
who are seeking new insights into the disease 
and its causative agent, the human immuno­
deficiency virus (HIV). In this issue's spedal 
feature, senior science writer Susan Blum sur­
veys AIDS research at the university and 
shows how the roots of this research often 
reach back to pioneering studies at 
Rockefeller that predate the AIDS epidemic, 
but that have proved remarkably relevant to it. 
COVER NOTE-This cover of Search features a rare, 
close-up look at HIV, the virus that causes AIDS. The elec­
tron micrograph shows a mature HIV particle-magnified 
about 640,000 times-attached to the "pit" in the surface 
membrane. This state represents the first step in the recep­
tor-mediated uptake of HIV. 
Despite the abundance of printed matter on HIV and 
AIDS, it was surprisingly difficult to locate a clear picture of 
the virus. Our search took us to the Aaron Diamond AIDS 
Research Center in New York, where we are indebted to its 
director, David Ho, to the Seminars in Virology editorial 
offices in London, and then to the Robert Koch lnstitut in 
Berlin, where Hans Gelderblom was extremely helpful. 
Gelderblom provided this micrograph, which originally 
accompanied an article by R.I. Connor and Ho, 
"Pathogenesis of Human Immunodeficiency Virus" that 
appeared in Seminars in Virology (volume 3, 1992). 
-The Editor 
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. 1t: 
I n 1969, the Surgeon General of the United States declared tha� the 
war against infectious diseases had been won. But clearly this procla­
mation of victory was premature. With the appearance of HIV ..and the AIDS 
pandemic, and the emergence of antibiotic-resistant strains of pathogenic 
bacteria across the world, infectious diseases remain a fundamental threat to 
all of humankind. This issue of Search features a comprehensive review of 
AIDS research at The Rockefeller University, covering the many facets of the 
university's effort to better understand HIV and design new methods to 
combat it. 
The Rockefeller University was founded in 1901 as The Rockefeller 
E s b; .E N 
, .. 
�' 
't ,# 
,,j 
Institute for Medical Research with the central mission of understanding the lethal secrets of dis-
i. ease-causing microbes and us!ng this knowledge to design specific anti-microbial therapy. Since · that time, this uhiversity has helped launch the antibiotic era and pioneer basic and clinical
research into the mechanisms of microbial pathogenesis. As the review of AIDS research at The
Rockefeller University demonstrates,. this historic commitment continues here today. 
From the university's beginning, many of its research programs have stemmed directly from 
the urgent publi� �ealth needs of New York City and other urban centers. This issue of Search
begins with a repo�t deliv�re·d at the uni_versity this past spring by New York City's top public
, health offidal,,M,argiret Hamburg,; bn the interloc½ing challenges of AIDS, tuberculosis, and drugaddiction. In addition, on July 21, 1993, the university sponsored a workshop on a growing crisis
that has been exacerbated by the_ AIDS pandemic: the global emergence of antibiotic-resistant
strains of deadly bacteria. The meeting, which included some of the nation's leading experts on 
public l}.ealth and)nfectious diseases, was the first step in a larger university program focused on 
the probl�m of drn'g_jresistant mid-ob,es. The Rockefeller Univedity intends to continue to play a
leading role in �esearch into the mechani�ms of antibiotic resistance, the development of new
and more specific �ntimicrobial therapies, and the dissemination of information to physicians and
scientists working at other, institutions reg.:i.rding this growing medical crisis. With our strengths in 
microbiology and molecular biol?gy, the clinical research capabilities of The Rockefeller
University Hospital, and our conra�ts with_ hospitaJs and, research institutions around the world,The Rockefeller University is uriiq�ely positioned to continue 'its historic mission into the twenty-
first century.
� -'-_ v·-_ . _·:: i'. ,,f�. cuJ� 
t. ' Torsten Wiesel President 
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TriP.le­
Heatted 
Disease 
Threat 
New York City 
Health Commissioner 
Addresses Three Related 
Epidemics at Rockefeller 
University Meeting 
In May 1993 the worlds of sci­
entific research and public 
policy came together for an 
unusual meeting convened at 
The Rockefeller University. 
Sponsored by The Rockefeller 
University Council-a. group 
of 160 friends of the university 
who promote public awareness 
of the importance of basic 
research in disease prevention 
and treatment-the meeting 
add ressed the increasingly 
interconnected urban health 
crises of AIDS , tuberculosis, 
and drug addiction. For The 
Rockefeller University, founded 
in 1901 as the nation's first 
biomedical research center, 
the gathering reflected its long­
st anding commitment to 
understanding and conquer­
ing infectious diseases. The 
panel of speakers included 
three leading Rockefeller 
researchers-Dr. Vincent Dole, 
Dr. Mary Jeanne Kreek, and 
the late Dr. Zanvil A. Cohn­
as well as New York City's 
Health Commissioner, Dr. 
Margaret A. Hamburg .  The 
work of the three Rockefeller 
investigators is covered in the 
article that begins on page 8 
(see The Battle Against AIDS). 
Following is a discussion of the 
remarks made by Hamburg. 
Y 
ou cannot live in a city like 
New York today without 
being in some way affected 
by the triple-headed disease 
threat of drug addiction, 
tuberculosis, and AIDS," Hamburg 
began by telling the audience. 
These three diseases are closely 
interrelated-primarily because many 
of the same factors underlie the inci­
dence and spread of each: poverty, 
unemployment, inadequate access to 
where, Hamburg explained, the 
reemergence of TB is connected to 
the AIDS epidemic because people 
whose immune function is seriously 
compromised are more susceptible 
to the disease. Hamburg estimated 
that as many as 40 percent of the 
city's TB patients are also infected 
with HIV. With as many as a quarter 
of a million New Yorkers already 
HIV positive-and hundreds of thou­
sands still at risk of AIDS-the num-
In her talk, Commissioner Margaret Hamburg stressed that society can no longer afford to neglect the 
burgeoning and interconnected urban health crises of AIDS, tuberculosis, and drug addiction. 
health care, substandard housing, 
and homelessness. And this connec­
tion is not unique to New York City. 
"Poverty is a primary force fueling 
the crisis in public health throughout 
the country," Hamburg said. 
Three Overlapping Epidemics 
The United States as a whole has 
experienced a 143 percent increase 
in the incidence of tuberculosis since 
1980, and New York's case load is 
disproportionately high, accounting 
for about 15 percent of the nation's 
cases. Poverty alone cannot account 
for this resurgence. Here, as else-
ber of people susceptible to TB 
infection is significant. 
To make matters worse, TB is 
much harder and more complex to 
treat in people with AIDS. "Even 
more alarming," according to 
Hamburg, "the recently documented 
outbreaks of multidrug-resistant TB 
in New York City have dispropor­
tionately involved HIV-infected 
individuals." 
Even without the additional bur­
den of TB, Hamburg said, AIDS will 
continue to take an enormous toll. It 
is already the leading cause of death 
among both men and women aged 
5 
:t:Wenty-five to forty-four in the city. 
The combination of AIDS and TB is 
especially deadly. 
Fueling both of these overlapping 
epidemics is the problem of drug 
addiction. The use of shared 'intra­
venous, needles is a major m�de of 
t�;;ihsmission of HIV; in , addition, 
drug addicts often engage: in uns:afe 
sex'ual 'practices. The r,esult is thataddict�, their partners, and. their 
unbprn children are p lated at 
increased risk for AIDS and TB. 
l� New York, with approximately 
200,00,0 intravenous drug users, IV 
drug u,se is linked either directly or 
through a sex partner's IV drug use 
to !the, majority of new HIV infection� 
in men and women and is responsi­
ble for almost 80 percent of pediatric 
AIDS cases, Hamburg asserted.' Many ' of the h�meless 
are al.so HIV 
"There is a substantial and 
growing population which 
is either already suffering 
from a combination of TB, 
AIDS, and drug addiction, 
or is at increased risk 
for disease." 
positive and 
addicted to 
drugs. 
These fac­
tors make it 
more difficult 
to treat and 
cure TB infec­
tions. They 
have also con­
tributed to the
rise in drug­
resistant strains. 
"Partial or non-completion of the six 
to nine months normally required to 
treat and cure TB fosters recurrence 
of inf e<;tious TB and the emE!rgence 
of dr�g-resistant strains. Those indi­
viduals ._can then transmit; 9rug-resis­
tanf 1:'B to othe.rs)1nd 'will require ad;9Jt'ional and,_c9s{lyJreatrri�nt t�em-;. .. 
sef�es:" the co'mr£"iisfuiler'1ipiairi�d. -:· 
c Furthermore, many of these indi­
viduals obtain temporary housing in 
911,e of the city's networks.' of shelters 
a_�d periodically serve time in the city's· criminal justice system. Many 
�f the shelters and jails are "poorly 
ventilated, overcrowde0d congregate 
settings-ideal breeding grounds for 
thi: ,spread of an airborne disease 
li�e TB;'' she said. 
, ,, ffamburg was blunt in her assess­ment. "There is a substantial and 
:J . - �  
-; j 
' ;, 
, · .  
growing population which is either 
already suffering from a combination 
of TB, AIDS, and drug �ddiction, or is at incre.ased risk for disease 
because of social circumstance·s, 
weakened health status, and height-
. ened risk of exposure." 
Strains in the System 
These, three epidemics .place an 
"almost unbearable strain on an 
�lready overburdened health care 
system," said Hamburg, who oyer­
sees a department with a $300 mil­
lion budget and more than 4,000 
employees. Countless New Yorkers, 
manY; without health insurance or 
access to routine care, many home­
less, drug addicted,, and. suffering 
from AIDS and TB, must use the 
emergency rooms as their provider 
of first and last resort. This leads to 
spor�dic treatment, inadequate med­
ical care, and "terribly high burnout 
rates" for medical staff. 
In addition, the commissioner 
said, our failure to recognize the vital 
role of public health and our focus 
on treatment rather than prevention 
has exacerbated these problems: 
"The infrastructure of public health 
has been terribly undermined over 
the past decade as a result of contin­
uous budgetary cuts and thoughtless 
consolidation of agencies and pro­
grams." As a re�ult, many core func­
tions of public -health, such as dis­
ease surveillance and epidemiology, 
outreach, prevention, education, 
infectious disease control, _protection 
against environmental threats to 
health, and quality assurance have 
been Compromised. 
This Jailure has cQntributed to the 
ree-mergence. of TB �nd other dis­
eases once deemed eradicated or 
' under control. Once effective anti-TB 
drugs were introduced., there was no 
further effort to li0mit r:iosocomial 
spr;ead or to moqit�i;' TB patients 
- aft�r_ discharge. TB trea�menrt pro­
grams; like casei rrfanage'ment and
, supervised tht;rapy, never, r�'ceive'd
enough supp�}ft. In addition, aware�
ness and trairiing about 1:B, along
with its appropriate management
and treatment, diminished. This ham-
pered the ability to rapidly and effec­
tively diagnose and treat TB, and 
resulted in fewer facilities for TB 
control. 
"And so,'" Hamburg concluded, 
"despite full kn'�wledge of how to 
prevent, control_;._and even cure­
TB; we are Stru�gling to cope with restlrgent di$easJ". ";·, 
P�eve·ntion · and Public Health 
k .' i ' Hambui:g ,em'phasized that we 
can no longer af�9,rd the costs of 
neglecting medi<5:al problems until 
they pose an immediate threat to 
pµbli,c health .. "W� ,spend billions of 
dollars oh medical care that could 
ha've been ave;rted had we been will­
ing ·to invest in prevention. For 
iilstartce, ·· drug 1adpiction costs this 
city countless ;d�hars 'in lost produc­
tivity, law �nfor�:e,ment efforts, and 
health care co,sts�not to mention 
the terrible cos� g.aid in wasted lives, 
Yet there'are fe��� than 44,000 drug 
treatment slots' available to serve ' • · ,  · 1 + '  well over one_.hqlf million New 
Yorkers who may, need drug'treatment.'1 , In the f�ce of' th�se challenges; 
H;irt1burg said.�Ei' must reaffirm our 
co�mitment t� the goals of preven­
ti�n .and to pub)'i s= health as well as. 
being IT).Ore creMi:Ve in devising 
methods to tackle ·today's public 
health threatsi Tq �ombat these __ dis.: 
eases effectively, we must acknowl� 
'edge economic realities. In certain 
instances this may mean providing 
stable housing or supportive sociat 
services-counseling, entitlement 
assistance, life skills training, and 
linkage with substance abuse and 
alcohol treatment programs. 
Both AIDS and drug addiction are 
illnesses rooted in individual behav­
iors, Hamburg said, and the develop­
ment and treatment of active TB are 
directly influenced by an individual's 
ability to comply with prescribed 
treatment. 
"Clearly, better understanding of 
how to reduce dangerous behaviors 
( like intravenous drug use and unsafe 
, sex, �nd ,how to increase treatment 
' compliance are critical to our efforts 
to contain these diseases," she said. 
, "Yet our investment in behavioral 
research has been woefully inade­
quate." 
Need for Basic Research 
The commissioner emphasized 
that research is an essential compo­
nent of public heath. She said: "It is 
. to research that w,re turn for new 
drugs, better delive'ry ·systems, new 
diagnostics that are faster, cheaper, 
and easier to use, improved thera­
peutic interventions, and, if we are 
lucky, vaccines." 
In particular, more basic research 
into the nature and mechanisms of 
these diseases is paramount. "We 
need to increase our knowledge of 
the nature of the tuberculosis organ-
" ism and the body's immune response 
to it so we can employ the best 
strategies for diag;nosis and treat-
ment. We desperately need t:o devel­
op new drugs and new intervention 
strategies. 
"Simultaneously, our efforts to 
better understand AIDS �ust contin­
ue and expand. We have not. yet 
grasped the full nature of the AIDS 
virus_ or the immune response to 
infection with this virus; nor have we 
identified drugs that can safely and 
effectively kill the virus or ihterrupt 
·its replication. And of ·course, we
must continue to support efforts to 
create an effective vaccine." 
Research into the nature and 
treatment of addiction h�s- perhaps 
been th� most woefully lacking of 
all, �amburg added, _and
,1
concerted 
efforts must move· forward on all 
these 'fronts. 
Hamburg reiterated that research 
Speakers at a panel on urban· health crises held at The 
,Rockefeller University thi·s,spririg included (from left to 
right) Professor Emeritus Vincent Dole, New York City 
Commissioner of Health Margaret Hamburg, Associate 
Professor Mary Jeanne Kreek, and the late Professor and 
Vice President for Medical Affairs Zanvil Cohn. 
must be part of a much broader 
effoi-t. 1 "We must make certain 
that we continue 
to adyocate force'... 
fully for a robus·t 
public health sys-
tern. , We must. i strengthen our 
commitment to 
prevention ef­
forts. And we 
must remain 
fully cognizant 
of thrc social 
forces that propel 
these deadly epi­
demics. As a city 
and as a nation, 
we can no lo.ng-
"We �ave not yet grasped 
the full nature of the AIDS 
virus or the immune 
response to infection with 
this vi,rus; nor have we identi­
fied dwgs that can safely 
and effectively kill the virus 
or interrupt its replication." 
er afford the consequences of 
negle�ting these concerns." 
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The human immunodeficiency virus (HIV) turns infect­
ed cells into factories for new viral particles. This 
electron micrograph gives a dramatic view of new 
viruses (small black dots) assembling at the surface 
of a cell and budding from it. (Photo courtesy of 
Associate Professor Gilla Kaplan.) 
BATTLE AGAINST 
V 
by Susan Blum 
iruses are nature's canniest 
pathogens. Extraordinarily
small, they must of neces­
sity travel light, packing only 
their genes wrapped up in a protein 
coat. Most of the genetic information 
they carry is devoted to accomplishing 
their modest goals: reproducing within 
a cell and introducing themselves into 
other cells. To do their dirty work, 
viruses mobilize the machinery of the 
cells they infect to produce all the pro­
teins they need to survive, thrive, and 
propagate. 
Of all these efficient intracellular 
parasites, none is more clever than the 
human immunodeficiency virus 
(HIV)-the virus that causes AIDS. Not 
only does HIV commandeer the body's 
protein-production equipment, but it 
disarms its defenses, as well. HIV's 
prime targets are cells central to 
immune-system functioning-the 
helper T cells that turn on and amplify 
many immune-system responses, and 
the macrophages that help rid the 
body of pathogens and the cells they 
infect. By disrupting immune-system 
functions in numerous ways, infection 
with HIV sets the stage for the diseases 
that eventually claim the lives of peo­
ple with AIDS, including opportunistic 
infections (such as Pneumocystis 
carinii), rare cancers (such as Kaposi's 
sarcoma), and tuberculosis. 
The devastation caused by HIV is 
overwhelming, with no end in sight. 
The World Health Organization 
(WHO) estimates that more than one 
million people are infected with HIV in 
the United States, and another fourteen 
million are infected elsewhere around 
Susan Blum is senior science writer in The 
Rockefeller University Public Affairs Office. 
9 
the globe. More than three-quarters 
of all current HIV infections are in 
Africa, but the epidemic is now 
growing most rapidly in Asia where, it 
is predicted, the number of new 
infections will soon outpace those in 
Africa. WHO estimates that by centu­
ry's end, the total number of HIV 
infections will reach forty million. 
The world desperately waits for 
an end to this plague, but as yet 
there is neither a cure for those 
already infected with HIV, nor a vac­
cine to protect those who are not. As 
researchers strive to devise better 
strategies to treat and prevent AIDS, 
they face many unanswered questions. 
How, for instance, does the virus 
wreak its havoc on the immune sys-
tern? Can the body's defenses be bol­
stered once infection occurs? Why do 
some people succumb to the virus 
sooner than others? What types of 
immune responses must be elicited 
by a successful vaccine or immune 
therapy? At what stages might the 
viral life cycle be blocked? What 
functions are served by the various 
HIV genes? What measures can be 
taken to prevent the spread of infec­
tion with HIV? 
Researchers at The Rockefeller 
University are among the thousands 
of scientists worldwide who are ask­
ing these questions-and others-in 
an attempt to conquer AIDS. They 
bring to their quest a unique combi­
nation of perspectives and scientific 
talents to attack HIV from all quar­
ters, including molecular biology, 
virology, infectious diseases, 
immunology, and patient-oriented 
studies. Often, the roots of their 
research reach back to pioneering 
studies begun decades ago in 
Rockefeller labs-studies 1that 
predate the AIDS epidemic, but that 
have proved remarkably relevant 
to it. 
In the pages that follow, Search 
chronicles some of the AIDS 
research being conducted on cam­
pus. The scope and variety of these 
studies reflect the many challenges 
scientists face as they try to outsmart 
one of the most savvy pathogens 
they have ever had to confront. 
Confronting HIV: The Immune System versus the Virus 
Researchers in the Cohn-Steinman laboratory explore hovv the immune 
system responds to HIV and hovv that response might be bolstered 
D espite more than a decade of research, scientists studying AIDS still do not know in 
detail how the immune system 
responds-and how it is impaired­
w hen confronted with HIV. 
Underlying this mystery is the extra­
ordinary complexity of the immune 
system itself. Countless details 
remain to be learned. 
Many features that are known so 
far about the immune system come 
from the pioneering research of sci­
entists in the Rockefeller laboratory 
headed by Ralph Steinman and, until 
his recent death, Zanvil Cohn. There, 
scientists are combining basic lab 
research with medical studies of spe­
cific diseases conducted at The 
Rockefeller University Hospital. 
Among the diseases under investiga­
tion are AIDS and tuberculosis (TB), 
a disease often associated with AIDS 
and exacerbated by it. 
The laboratory's clinical and basic 
studies cover a wide range of ques­
tions relevant to AIDS, including the 
function of specific immune-system 
cells, their regulation, the interac-
10 
tions among them, their beneficial 
and harmful effects, and the ways 
those effects might be manipulated 
to treat disease. 
The researchers focus on a type 
of immune-system response known 
as cell-mediated immunity. As its 
name implies, this arm of the body's 
One aim of the researchers 
is to boost beneficial 
immune-system responses 
to HIV Another is to 
diminish responses that 
might be harmful. 
defense repertoire pits immune-sys­
tem cells directly against cells in the 
body that have been infected with 
bacteria or viruses (see illustration, 
page 13). The other arm of the 
immune system-known as humoral 
immunity-mobilizes proteins called 
antibodies, which travel through .the 
blood and the lymph system and 
neutralize pathogens before they can 
infect cells. 
One type of immune-system cell 
is the macrophage, a cell that was a 
special research interest of Cohn's. In 
fact, his work was so central to the 
understanding of macrophages that 
Cohn was widely acknowledged to 
be the "dean" of macrophage stud­
ies. Macrophages kill in a number of 
ways, but their primary modus 
operandi is phagocytosis-a process 
of engulfment that sequesters and 
kills both free-floating microbes and 
the cells they infect. 
T cells, or lymphocytes, are 
another class of immune-system 
cells, whose various names reflect 
the specialized proteins they sport 
on their surfaces. "Cytotoxic" CDS T 
cells, for instance, engage in cell 
killing. CD4 T cells, or "helper" T 
cells, orchestrate a wide range of 
defensive responses through their 
effects on many other immune-sys­
tem cells, including macrophages, 
CDS T cells, and the cells that make 
,...., 
Above, Associate Professor G i I la 
Kaplan and Postdoctoral 
Associate Andre Moreira study 
how the drug thalidomide inhibits 
the activation of HIV. Below,
Professor Ralph Steinman con­
ducts research with Postdoctoral 
Associate Melissa Pope on den­
dritic cell-COB T cell interactions, 
and with Clinical Scholar Ian Tang 
'on the effect of interleukin-2 on 
COB T cell.s. 
1 1 
antibodies. The catastrophic effects 
of AIDS are largely due to the fact 
that HIV infects these CD4 T cells, 
which are so vital to immune-system 
functioning. 
Dendritic cells, whose existence 
was discovered by Steinman and 
Cohn, are yet another type of 
immune-system cell. Dendritic 
cells serve as sentinels that 
scout out "foreigners" 
such as invading 
pathogens, and pre­
sent fragments of 
these foreigners 
(called antigens) 
to CD4 and CDS 
T cells, which 
can then re- /. 
spond. Natural 
killer cells, or 
NKs, (many of 
whose functions 
were elucidated 
in the Cohn­
Steinman lab) and 
lymphokine-activat-
e d killer cells, or 
LAKs, are additional 
types of immune-system 
cells that can also destroy 
infected cells in the body. 
Goading the various immune­
system cells into action are a wide 
range of proteins called cytokines. 
These hormone-like substances are 
produced by certain immune-system 
cells (notably CD4 T cells) and, in 
complicated biochemical feedback 
loops, induce immune cells to devel­
op, proliferate, and become activat­
ed. Numerous cytokines have been 
under investigation in the lab for 
years, with particular emphasis on 
patient-oriented studies exploring 
how cytokines may modulate the 
immune response and affect disease 
states. 
For example, a pioneering series 
of AIDS studies began in 1990, using 
a cytokine named interleukin-2 (IL-
2). IL-2, produced by CD4 T cells, 
stimulates a wide range of other 
immune cells, such as CDS T cells, 
NKs, LAKs, and CD4 T cells them­
selves. Ever since genetic engineer­
ing techniques first made it possible 
to manufacture "recombinant" IL-2, 
the Rockefeller researchers· have 
been using the engineered product 
to amplify immune response in a 
number of diseases, first with leprosy 
and now also with TB and AIDS. 
"Given that AIDS is characterized by 
a depletion of CD4 T cells-the very 
cells that produce IL-2-we reasoned 
that IL-2 therapy might prove useful 
in the treatment of people .with 
AIDS," says Gilla Kaplan, a scientist 
in the lab. The therapeutic studies, 
conducted at The Rockefeller 
University Hospital, used low doses 
of the genetically engineered IL-2, 
unlike the higher, toxic doses of IL-2 
used by researchers elsewhere to 
treat cancer. 
The results of the lab's first, 
short-term trials were encouraging: 
individuals who received IL-2 
showed an increase (in some cases) 
or stabilization (in others) of CD4 T 
cell count-a clear benefit for those 
infected with HIV. They also showed 
an increase in the number and activi­
ty of both NKs and LAKs-increases 
Dendritic cells scout out foreign invaders and 
present them to other immune-system cells. 
which can then respond. Above, T cells cluster 
around a dendritic cell. 
which might help eliminate HIV­
infected cells, cells infected with 
opportunistic pathogens, or both. 
Longer-term- studies of the effects of 
low doses of IL-2 in patients with 
AIDS and/ or TB on CD4 T cells and 
nonspecific killer cells are now getting 
under way directed by Kaplan. 
In a related line of patient-ori­
ented AIDS research, studies 
of IL-2's effects on another 
component of the cellu­
lar immune system­
CDS T cells-are 
under way under 
Steinman's direc­
tion. He and his 
colleagues have 
long been ex-
ploring the func­
tion of these 
cells. Unlike 
NKs and LAKs, 
which respond to 
a wide range of 
antigens, each 
"clone," or group, 
of cytotoxic CDS T 
cells is genetically pro­
grammed to respond to 
just one of a pathogen's 
antigens. 
Steinman explains, "HIV mutates 
very rapidly, allowing it to outfox the 
antibody limb of the immune system. 
But it is much harder for HIV to 
escape killer CDS T cells, since they 
recognize parts of the virus that do 
not mutate." Thus, he and his col­
leagues are eager to see whether 
boosting CDS T cells' activity might 
improve the body's ability to rid 
itself of HIV-infected cells. 
Steinman also plans to explore 
whether interactions with dendritic 
cells might boost CDS T cell activity. 
Dendritic cells normally present anti­
gen to both CDS and CD4 T cells; in 
so doing, they stimulate those cells 
into action. 
Over a year ago, Steinman and 
his colleagues showed how dendritic 
cells can be key players in the loss 
of CD4 T cells that is a hallmark of 
AIDS. They found that intact HIV 
"hitchhikes" on dendritic cells that 
carry the antigens of other pathogens 
THE CELLULAR IMMUNE SVS_TEM 
Helper T cells (CD4 T Cells) 
These cells play a key role in the body's 
defense system. CD4 T cells orchestrate 
a wide range of immune responses. They 
stimulate CDS T cells and other killer 
cells, macrophages, and the cells that 
produce antibodies. 
------ Dendritic cells 
Interferon gamma 
This is a hormone-like substance, or 
cytokine, that is produced by CD4 T cells 
and stimulates macrophages and other 
immune-system cells. 
TNF-alpha 
Interferon 
gamma 
IL-2 
Macrophages 
These cells engulf and 
kill pathogens. 
IL-2 
TNF-alpha 
This is a cytokine that is produced by 
macrophages and other immune-
system cells. TNF-alpha prompts a num­
ber of beneficial immune-system respons­
es, but too much of it can be harmful. 
to CD4 T cells. As the CD4 T cells 
cluster around the dendritic cell and 
are activated by it in response to the 
antigen, they are also infected with 
the bystander HIV. Then, the CD4 T 
cells become a syncitium-one giant 
cell with many nuclei. The result: an 
"explosive" CD4 T cell infection and 
massive cell death. 
Ironically, though, another aspect 
of dendritic cell functioning may 
actually help the body fight infection 
with HIV. In studies at The 
Rockefeller University Hospital, 
Steinman and his colleagues plan to 
remove dendritic cells from people 
infected with HIV, manipulate the 
cells in the test tube so they present 
particular HIV antigens (not the 
whole virus), and then reintroduce 
the cells into the infected individual 
in an attempt to amplify CDS T cell 
response. The researchers believe 
they will be able to manipulate the 
dendritic cells so that they present 
the HIV antigen only to CDS T cells, 
and not to CD4 T cells. 
While one aim of the lab's 
research is to boost beneficial 
immune-system responses against 
HIV, a parallel aim is to diminish 
responses that may be harmful. One 
such harmful response is the over­
production of TNF-alpha, a potent 
These cells serve as sentinels to scout 
out "foreigners" such as invading 
pathogens. They present fragments of 
these foreigners (called antigens) to CD4 
and CDS T cells, which can then respond. 
Interleukin 2 (IL-2) 
This is a hormone-like protein, called a 
cytokine, that is produced by CD4 T cells. 
IL-2 stimulates and activates a wide vari-
. ety_of immune-system cells, including 
CD4 T cells themselves. 
These cells attack other cells that are infected 
by viruses or bacteria. Some killer cells (CDS T 
cells) carry the CDS protein, which helps the 
cell reco.gnize pathogens. Other killer cells, 
known as natural killer cells and lymphokine­
activated cells, do not carry the CDS protein. 
cytokine produced by macrophages 
and other immune system cells when 
viruses and bacteria invade the body. 
Some TNF-alpha is vital for the 
body's defensive maneuvers, but too 
much of the substance can produce 
debihtating fevers, weight loss, and 
fatigue that seriously impede a per­
son's ability to combat disease. 
Patients with TB produce too much 
TNF-alpha. So do patients with AIDS, 
as a result of their opportunistic 
infections and, perhaps, as a result 
of infection with HIV itself. 
The scientists' studies of TNF­
alpha have their roots in the lab's 
long-standing interest in leprosy. 
Illustrations by Terese Winslow . 
., 
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THE STRUCTURE OF HIV 
gp41 
Reverse transcriptase 
Viral envelope 
RNA 
The material of which HIV's genes are made. 
RNA is a close molecular cousin of DNA, the 
more common genetic material. 
Reverse transcriptase 
The viral enzyme that makes a DNA copy of 
HIV's RNA genes. 
Viral envelope 
The virus's fatty membrane coat. It is derived 
from the membranes of the cells that HIV 
infects. 
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gp120 and gp41 
Two proteins embedded in the virus's fatty 
coat (also called its envelope). The proteins 
are produced from a precursor protein called 
gp160. gp120 binds to CD4 receptor proteins 
on the surface of helper T cells and 
macrophages. In ways that remain unknown, 
gp41 is involved in the fusion of the virus 
with the cell it infects. 
p17 
p24 
p7 and p9 
p17 and p24 
Two proteins coded for by an HIV gene 
called gag. Molecules of p17 surround the 
inner portion of the HIV envelope. Molecules 
of p24 make up the capsid, or core - the 
structure that surrounds the virus's RNA 
genes. 
p7 and p9 
Two proteins coded for by an HIV gene 
called gag. They are both believed to bind to 
the virus's RNA genes. 
While treatment for leprosy is effec­
tive, it can lead to serious side 
effects. For a quarter of a century, 
doctors successfully combated those 
side effects with the drug thalido­
mide, although they did not know 
why the therapy worked. Recently, 
however, research by Kaplan and 
her colleagues disclosed that thalido­
mide selectively inhibits TNF-alpha, 
while leaving other beneficial defen­
sive responses intact. They have 
recently begun clinical trials of 
thalidomide to combat the effects of 
excess TNF-alpha in people with 
AIDS and/or TB. The initial results, 
which include dramatic weight gain 
and reductions in fever, have been 
extremely promising. 
The Rockefel ler University 
researchers' most recent studies indi­
cate that thalidomide may prove use­
ful in combating not only the symp­
toms of AIDS, but the replication of 
its causative virus, as well. As it turns 
out, TNF-alpha is an extremely 
potent trigger for the activation of 
HIV genes that have been integrated 
into a host cell's genes and lie dor­
mant there. (See illustration, page 
18.) When TNF-alpha is produced in 
response to infection (such as with 
an opportunistic pathogen), the dor­
mant HIV genes are turned on at the 
same time as immune-cell genes that 
are mobilized to fight the infection. 
In this way, HIV "parasitizes" the 
regulatory mechanisms of immune 
cells for its own purposes. 
Test-tube experiments by Kaplan 
and her colleagues have already 
indicated that thalidomide can stop 
HIV replication in certain laboratory 
cell lines, as well as in blood cells 
taken from patients and grown in 
culture. In ongoing clinical trials at 
The Rockefeller University Hospital, 
the researchers are now administer­
ing thalidomide to people with AIDS 
(with and without TB) to further 
explore the promising indications 
that thalidomide might provide an 
effective new therapy in the fight 
against AIDS. 
A Budding Subject: Hovv HIV Escapes from the Cell 
In the Aderem lab, studies of interactions betvveen proteins and mem­
branes may yield strategies that keep HIV from assembling vvithin an 
infected cell and moving out to infect others 
V
iral infections progress when 
viruses harbored within host 
cells multiply, leave, and go 
on to infect other cells. Before HIV 
can leave a cell, one of its proteins­
called pSS gag (or pSS, for short)­
must get to the host cell's mem­
brane. There, the virus assembles, 
with pSS providing the scaffold. 
Once assembled, the virus buds off 
from the membrane, and pSS is 
cleaved to form a number of pro­
teins, including p24, pl 7, p9, and 
p 7. (See illustration, page 14.) 
In this process of assembly, as in 
many other process­
es, HIV hijacks the 
host cell's machinery 
for its own purpos­
es. It induces a cel­
lular enzyme to 
place a specialized 
substance on pSS. 
This substance, cal­
led myristic acid, is a 
fatty molecule that 
decorates at least 
fifty cellular proteins 
and helps them bind 
to membranes. It 
Associate Professor Alan 
Aderem and Postdoctoral Fellow 
Jennifer Darnell are pursui,ng 
ways to keep HIV from assem­
bling within infected cells. 
Because HIV hijacks the 
cell's own machinery, 
many anti-HIV strategies 
can impair the cell's 
normal functioning, too. 
The goal is to find a strat­
egy that is specific to HIV. 
serves the same purpose for pSS. 
Myristoylation-the addition of 
membrane-attaching myristic acid to 
proteins-has long been a subject of 
interest for Alan Aderem. As a 
researcher in the Cohn-Steinman lab, 
while investigating how immune 
cells called macrophages respond to 
external messages, he discovered 
two myristoylated proteins called 
MARCKS and MacMARCKS. These 
proteins are still under intensive 
study in his own lab, which he has 
headed since 1991. 
MARCKS is now known to occur 
in virtually all cell 
types, while Mac­
MARCKS' distribu­
tion is more limited. 
The specific func­
tion of these two 
"MARCKS brothers" 
varies among cell 
types, but in general 
they appear to facili­
tate interactions 
between cellular 
membranes and the 
cytoskeleton-the 
filamentous protein 
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backbone that gives a cell shape and 
allows it to move. 
In macrophages, such mem­
brane-cytoskeleton interactions are 
vital for phagocytosis and endocyto­
sis-the processes by which the cells 
engulf and incorporate particles such 
as pathogens and dead or dying 
cells. The interactions may also be 
vital for viral budding-a process 
which, Aderem points out, appears 
to be the opposite of endocytosis. In 
one case, a particle-such as a 
pathogen-must be brought into the 
cell and somehow maneuvered 
through the cytoskeletal framework. 
In the other case, a particle-the 
virus-must make its way out 
through the cytoskeleton. 
This intriguing analogy has led 
Aderem and his colleagues to add 
studies of HIV assembly and bud­
ding to the roster of projects under 
way in their lab. They are pursuing 
the subject in the two main cell 
types infected by HIV: CD4 T cells 
and macrophages. 
It is well established that newly 
assembled HIV buds off from the 
CD4 T cell's surface membrane, 
thereby killing the cell, but what 
happens in macrophages-where 
the virus does not bud outward-is 
less w�ll understood. One model 
holds that in macrophages myristoy­
lated p55 binds to internal mem­
branes. The virus then assembles 
and "buds" into the compartments 
the membranes surround. Thus, 
macrophages can serve as HIV reser­
voirs. When these cellular storehous­
es eventually die, they release their 
burden of infectious virus. In 
the brain, where specialized 
macrophages called microglia are 
infected by HIV, such a process may 
cause the dementia that is often a 
symptom of AIDS. 
What might direct myristoylated 
p55 to different membranes in differ­
ent cell types? Aderem and his col­
leagues speculate that these proteins 
might link up with specific receptors 
studding the membranes in question. 
They are currently hunting for these 
receptors, bolstered by the knowl­
edge that they have already discov­
ered candidate receptors for the 
myristoylated forms of MARCKS and 
MacMARCKS. 
If receptors for myristoylated p55 
can be found, it might eventually be 
possible to block them, thereby fore­
stalling p55-membrane interactions. 
Such interventions would effectively 
stop HIV in its tracks, since the virus 
would no longer be able to assemble 
and bud. Experiments elsewhere 
have already shown that preventing 
the myristoylation of p55 also blocks 
HIV budding. But this strategy is not 
feasible for long-term therapeutic 
use, since it targets a cellular enzyme 
that controls many myristoylation 
events vital for normal cell function­
ing. "The goal," says Aderem, "is to 
block a pathway that is absolutely 
specific for the virus." 
Fateful Paths: Hovv CD4 T Cell Function Goes Avvry in AIDS 
Studies of T cell development and function in the Choi lab help illuminate 
the depletion of CD4 T cells, the immune-system orchestrators vvhose loss is 
so catastrophic in AIDS 
A s the disaster of AIDS attests, humans cannot survive with­out properly functioning T 
cells. But the critical importance of 
these cells is much better under­
stood than the mechanisms by  
which they obtain, and maintain, 
their defensive capabilities. 
Y ongwon Choi is investigating how 
T cells develop and function. 
Ultimately, his studies may also shed 
light on how their function goes awry 
in AIDS. 
During development, immature 
T cells undergo a complicated 
process of selection that allows only 
some of them to survive. This com­
plex enterprise involves the presen­
tation to T cells of "self-antigens"­
fragments of proteins that belong to 
the body's own tissues. In the course 
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of selection, Choi explains, "some 
developing T cells see self-antigen 
and live, while others see self-anti­
gen and die. It's a very intriguing 
contradiction." 
Choi is pursuing the cellular sig­
naling events at the heart of this 
contradiction, but his search is com­
plicated by the difficulties of study­
ing cells within developing mam­
mals. One way he circumvents this 
problem is to study other immune 
system phenomena that may shed 
light on T cell development. 
As part of his studies, Choi is 
investigating how CD4 T cells (the T 
cells depleted in AIDS) interact with 
a class of antigens known as super­
antigens. Rather than rousing one in 
10,000 or 100,000 helper T cells, a 
superantigen goads 25 or 30 percent 
of them into action. Oddly enough, 
once the superantigen-stimulated T 
cells have proliferated, they some­
times subsequently become inactive 
or self-destruct through a cell death 
program known as a poptosis-a 
process that recalls the death of T 
cells during development. 
When Choi was a postdoctoral 
fellow, he discovered that a mouse 
retrovirus called MMTV encodes a 
protein that can act as a su peranti­
gen. When MMTV is incorporated 
into an animal's chromosomes and 
passed to the next generation, the 
superantigen it encodes can provoke 
the destruction, or deletion, of a 
whole subset of T cells in the devel­
oping animal. But if MMTV infects a 
mouse after it is born, the superanti­
gen it encodes can cause the mas-
...... 
sive T cell proliferation characteristic of that 
induced by other superantigens. Like those 
superantigens, MMTV can also cause subse-· 
quent T cell inactivation or death. 
Might HIV-which, like MMTV, is a retro­
virus-also encode a superantigen? According 
to Choi, the evidence is suggestive, but mixed. 
Far more research is required to settle the 
Many researchers believe that 
only a small proportion of CD4 T 
cells are infected with HIV. 
Why, then, do so many CD4 T 
cells eventually die? 
question, and he hopes soon to begin such 
investigations. But should it turn out that HIV 
does not itself encode a superantigen, these 
immune-system superstimulators may still be 
involved in AIDS. "Many of the viruses already 
present in the body may encode superanti­
gens that are only produced when HIV is also 
present," says Choi. These activated superanti­
gens could contribute to the CD4 T cell deple­
tion seen in AIDS. 
Whatever the ultimate role of superanti­
gens in AIDS may turn out to be, Choi is 
hopeful that his fundamental interest in T cell 
development may yield clues about the dis­
ease. For instance, though the issue is current­
ly being debated, many researchers (Choi 
among them) believe that only a small 
proportion of CD4 T cells are infected with 
HIV. Why, then, do so many CD4 T cells even­
tually die? 
Choi points out, "If you present antigen to 
CD4 T cells from people who are HIV nega­
tive, the cells that are primed to recognize the 
antigen proliferate. But if you do the same 
thing with uninfected CD4 T cells of people 
who are HIV positive, the cells primed to rec­
ognize the antigen die, rather than proliferate." 
This paradox recalls the question that 
intrigues Choi about T cell maturation during 
development: Why do some T cells see self­
antigen and live while others see self-antigen 
and die? The phenomena look to Choi like 
two sides of the same coin. The challenge is 
to figure out how the coin is minted. 
Assistant Prnfessor Yongwon Choi (right) and 
Postdoctoral Associate Jang Won Choi are 
researching the mechanisms of T cell 
development and death. 
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THE LIFE CYCLE OF HIV 
From Infection of the Target Cell to the 1 Budding1 
of Nevv Viruses From the Cell 
HIV virus
1. HIV attaches to a protein
receptor, called CD4, found on
the surface of helper T cells and
macrophages.
2. The virus fuses with the host cell's
membrane and enters the cell.
3. The virus sheds its protein coat.
� 
\ #' ..... , 
4. A viral enzyme called reverse
transcriptase copies the viral
RNA into DNA.
Protein coat -;/_�Viral RNA �,-,,;,,·, 
/ - \ 
,r 
/ 
/
/ ' 
/ 
7. The virus commandeers the
cell's protein-production machin­
ery to "translate" the information
in viral mRNA into viral proteins.
Protein-production machinery 
\ 
Viral RNA genes 
8. The virus assembles itself andu
buds out of the cell.
Revealing Differences: Studying the Human Retroviruses 
Small in number but great in impact, the retroviruses that infect humans­
including HIV-are the subject of study in the Hall lab 
N
umerous retroviruses infect 
animals, but only four are 
known to infect human 
beings: the human immunodeficien­
cy viruses types 1 · and 2 (HIV-1 and 
HIV-2) and the human T cell 
leukemia viruses I and II (HTL V-I 
and II). Virologist William Hall spe­
cializes in the study of these human 
retroviruses. 
A physician as well as a basic 
researcher, Hall brings a special per­
spective to his studies. For instance, 
in studying HIV-positive intravenous 
drug abusers in the New York City 
area, he and his colleagues discov­
ered that about 13 percent of them 
are also infected with either HTLV-I 
or HTLV-II, with the vast majority 
being infected with HTLV-II. A num­
ber of previous studies have shown 
that people infected with both HIV 
and HTLV-I progress to full-blown 
AIDS and deteriorate faster than the 
average patient. In contrast, Hall has 
noted, the course of disease tends to 
progress more slowly than average 
in those co-infected with HIV and 
HTLV-II. 
What might contribute to these 
differences? Hall and his colleagues 
have found that HTLV-II infects CDS, 
or cytotoxic, T cells, unlike HIV and 
HTLV-I, which both infect CD4 
T cells, otherwise known as helper 
T cells. 
Profound differences in immune­
system responsiveness may result 
from these different patterns of infec­
tion. As Hall explains, "Because 
HTL V-I and HIV both infect the same 
cell population, they may well acti­
vate each other's replication," there­
by hastening the depletion of crucial 
CD4 T cells. 
On the other hand, Hall points 
out, CDS T cell counts are actually 
higher than normal in people who 
are infected with HTLV-II, and this 
may somehow bolster these persons' 
abilities to fight back when they are 
co-infected with HIV. 
Hall and his colleagues plan to 
pursue the role CDS T cells may play 
in combating AIDS. He is intrigued 
by studies conducted in San 
Francisco showing higher-than-nor­
mal CDS T cell counts in a group of 
homosexual men who are long-term 
survivors-that is, people who have 
remained well for over a decade, 
despite being infected with HIV. The 
men are not infected with HTLV-II, 
and the cause of their higher-than­
normal CDS T cell counts is not yet 
known. But the California re­
searchers studying the men report 
that their CDS T cells produce an as 
yet unidentified substance that 
inhibits HIV replication. 
Though interested in these 
reported results, Hall remains cir­
cumspect. "We really don't know 
Associate Professor William Hall (left} and 
Postdoctoral Fellows Shi Wei Zhu (center} and 
Takayuki Kubo study the human retroviruses. 
rn 
90 
what role C DS T cells may be 
playing, but we want to find ·out," 
he says. 
People infected witn 
both HIV and another 
retrovirus called 
HTLV-1 progress to 
AIDS and deteriorate 
faster than the aver­
age patient, while the 
course of disease 
progresses more 
slowly than average 
in those co-infected 
with HIV and HTLV-11. 
The question is why. 
He and his col-
leagues are also study­
ing HIV itself. While 
investigating how 
HIV's genes become 
integrated into the 
genes of the host cell, 
they found that an 
important part of this 
process involves �the 
activity of an enzyme, 
called a topoiso­
merase, that is encod­
ed by the HIV gag
gene-the same gene 
that codes for a num­
ber of the virus's 
structural proteins. 
They are now study­
ing a number of inhib­
itors of the topoiso­
merase to explore 
how they might be 
used as antiviral 
agents. In another 
research direction, they are studying 
the process by which a viral precur-
sor protein called gp160 is processed 
into HIV's two envelope proteins, a 
step that is necessary to complete 
the virus's. life cycle. They hope their 
research will disclose new ways to 
inhibit this process. 
They are also exploring the pos­
sibilities for an oral vaccine against 
AIDS. Using HTLV-I as a model, they 
have identified regions of viral pro­
teins that provoke neutralizing anti­
bodies-antibodies that attach them­
selves to the virus and prevent it 
from infecting cells. They plan to 
link peptides (short proteins) mim­
icking these regions to the B subunit 
of cholera toxin, or CTB, which can 
be used as a vaccine delivery vehi­
cle. CTB binds avidly to a molecule 
found in abundance on the surface 
of mucosal cells, the cells that line 
body cavities such as the mouth, gut, 
and genital tract. As a first step, Hall 
and his colleagues will test this 
model vaccine in rats, to see how 
well it evokes two different kinds of 
immune responses-one that works 
at mucosal surfaces, and one that 
operates systemically throughout 
the body. 
A Slovv and Stealthy Enemy: Hovv HIV Remains Latent 
Studies in the Baltimore lab aim to understand various aspects of latency­
the ability of HIV to remain silently hidden within cells 
M
ost interactions between 
virus and host occur rapid­
ly. Within a few days or 
months of being infected, people in 
whom a particular virus proves path­
ogenic have usually either success­
fully combated the virus or-occa­
sionally-succumbed to it. 
But infection with HIV is differ­
ent. During the course of AIDS, a 
person initially experiences a brief 
period of illness with certain symp­
toms (such as fever, chills, and 
malaise) and shows certain measur­
able signs (such as a dramatic 
increase of virus in the blood and a 
decrease of CD4 T cells). Then, 
although a slow decline of helper T 
cells may sometimes continue, the 
symptoms disappear, the blood's 
viral load abates, and the person 
usually stays well for a few years, a 
decade, or in rare cases even longer. 
Eventually, though, the virus makes 
itself felt once again. The CD4 T cell 
count plummets, the viral load in the 
blood soars, and the rare cancers or 
opportunistic infections that will ulti­
mately prove fatal set in. 
This typical course of disease, 
which includes the period of well­
being called "clinical latency," is by 
now well established, but the molec­
ular and cellular events underlying 'it 
are not. The basis of such molecular 
and cellular latency is a subject of 
study in the lab of David Baltimore, 
a virologist who earned his Ph.D. at 
Rockefeller and later served as its 
president. 
Baltimore has long had an inter­
est in retroviruses in general, and 
HIV in particular. For instance, he 
shared the Nobel Prize with Howard 
Temin in 1975 for their independent 
discoveries of reverse transcriptase, 
the enzyme that turns retroviral RNA 
genes into DNA. In the mid-1980s, 
his lab identified NF-KB, the key pro­
tein that regulates the readout of 
HIV's genes into a molecular inter­
mediate known as messenger RNA. 
And, in the late 1980s, his lab eluci­
dated the complex, two-stage 
process by which some HIV proteins 
are produced later than others. Only 
when the later stage of protein pro­
duction is finished can the virus 
assemble, leave the host cell, and go 
on to infect other cells. 
Baltimore and his colleagues are 
now using versions of the assays 
they developed for these viral life­
stage investigations to explore the 
molecular basis of latency as it is 
manifested in human disease. In one 
set of studies, they found dramatic 
differences between two subsets of 
HIV-positive individuals, all of 
whose CD4 T cell counts still looked 
normal. The researchers used an 
unusual treasure trove of blood sam­
ples provided by the New York 
Basic research by Profess�r David 
Baltimore (right) and Postdoctoral 
Associate Kalle Saksela may yield ways 
to provide more individualized treatment 
for people infected with HIV. 
Blood Center. A detailed medical his­
tory of each donor was available, so 
that molecular and clinical data 
could be assessed in relation to one 
another. 
The scientists found that 
the blood of those people whose 
disease would 
progress within a 
few years contained 
the instruction mole­
cules (messenger 
RNA) needed to 
produce both early­
and late-stage viral 
proteins, while the 
blood of those who 
would be long-time 
survivors-staying 
well 10 years or 
m o r e - s h o w e d  
either little or none 
of these messenger 
molecules. "Re-
The typical course of 
infection with HIV-
which includes the period 
of well-being called 
"clinical latency"-is 
by now well established, 
but the cellular events 
underlying it are not. 
searchers have been looking hard for 
a way to predict the fate of individ­
ual patients," Baltimore comments. 
"We're hopeful these assays can be 
used to identify people who can 
benefit from earlier therapeutic inter­
vention." 
Also yielding promising results 
are the lab's studies with chim­
panzees, conducted in collaboration 
with a French group headed by Dr. 
Marc Girard, Baltimore's first post­
doctoral fellow. 
Chimps can be infected with HIV, 
but do not develop AIDS. So far, the 
blood of the animals under study by 
the Baltimore team looks like the 
blood of human long-term survivors: 
that is, it harbors little or no HIV 
messenger RNA. But messenger RNA 
can be found in the animals' lymph 
nodes-a significant finding in view 
of recent reports that the lymphatic 
tissue of humans sequesters HIV 
(and so may serve as a reservoir) 
during clinical latency. Thus, the 
chimp may turn out to provide what 
has long been missing in HIV stud­
ies-a good animal model for afleast 
some stages of the human disease. 
In addition to their studies of 
humans and chimpanzees, the 
researchers are conducting investiga­
tions using two test-tube models of 
cellular latency. This research indi­
cates that more than one cellular 
mechanism might maintain latency 
on the molecular level, including a 
hitherto unidentified cellular factor. 
Baltimore and his colleagues plan to 
explore how these test-tube models 
might relate to human infection with 
HIV. The researchers hope these 
studies will eventually result in ways 
to bolster natural mechanisms that 
maintain latency. 
'Natural Allies': Exploring the Role of Natural Antibodies 
Researchers in the Allfrey lab are studying 'host factors' that may 
help delay the progression to AIDS 
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In the laboratory of Professor Vincent 
Allfrey (right), adjunct faculty member 
Toby Rodman studies natural antibodies 
to a protein made by HIV. 
T he period of time between ini­tial infection with HIV and the onset of AIDS varies greatly. 
Some people become ill within a 
year of infection, while others 
remain asymptomatic for a decade or 
longer. 
Why does this disparity exist? 
Investigators in the lab of Vincent 
Allfrey aim to shed light on this 
question. There, Toby Rodman and 
colleagues are exploring the possibil­
ity that "natural antibodies" are host 
factors-that is, substances produced 
by HIV's human "host"-that may 
help retard the progression to AIDS. 
Antibodies are proteins that travel 
through the blood, latching on to 
pathogens and facilitating their 
destruction. Exquisitely sensitive and 
specific to one particular pathogen, 
antibodies are normally produced 
after the virus or bacterium has 
invaded the body. But natural anti­
bodies are different: they are pro­
duced by the body independently of 
any challenge from a virus, bacteri­
um, or other agent. These pre­
formed antibodies may act as an 
early defense system against infec­
tious invaders. Although the exis­
tence of natural antibodies has been 
hypothesized for more than thirty 
years, until recently they received lit­
tle attention from the scientific 
research community. 
Rodman was not always involved 
in research on natural antibodies. 
Her ,initial studies focused on prota-
The period of time 
between initial infec­
tion with HIV and the 
onset of Al OS varies 
from person to person. 
The existence of 
"natural antibodies" to 
a protein produced by 
HIV may help explain 
this disparity. 
mine, a unique protein that packages 
DNA in the nucleus of sperm cells. 
Her interest in natural antibodies 
arose in the early 1980s from discus­
sions with the late Henry Kunkel, a 
Rockefeller immunologist. At that 
time, AIDS had been primarily identi­
fied in the male homosexual popula­
tion, and Kunkel and Rodman 
hypothesized that the constituents of 
semen, including sperm, might 
somehow play a role in infection 
with HIV. As an outgrowth of those 
discussions, Rodman and her col­
leagues discovered natural antibodies 
to protamine. 
More recently, they discovered 
natural antibodies to a protein pro-
duced by HIV itself. This protein, 
called Tat, plays a vital role in the 
virus's ability to make more copies of 
itself. Two different anti-Tat natural 
antibodies have been found, each of 
which targets a region that is essen­
tial for the protein's function. 
The anti-Tat natural antibodies are 
present in the blood of all HIV-nega­
tive people studied by the 
researchers. They are also present, in 
normal amounts, in people newly 
infected with HIV. But as HIV infec­
tion progresses, there is a corre­
sponding decrease in anti-Tat natural 
antibodies, and people with full­
blown AIDS have very low levels or 
none at all. 
"The correlation between natural 
antibody level and stage of disease 
suggests that the antibodies may be 
a factor that helps delay the progres­
sion to AIDS," says Rodman. One 
question that remains to be answered 
is why the levels of these antibodies 
-which start out just about the
same in all people-decline at vari­
able rates in persons progressing
toward AIDS.
Another question is how the anti­
bodies might work. In studies of HIV­
infected cells grown in a culture dish, 
Tat protein has been found in the 
fluid outside the cells. A number of 
research groups have speculated that 
in the body, Tat protein may also 
leave HIV-infected cells that are 
actively producing new virus. If this 
occurs, then the anti-Tat antibodies 
might prevent this extracellular Tat 
from entering HIV-infected cells that 
are not yet producing virus and acti­
vating the HIV genes that lie dormant 
within them. Another possibility 
is that the antibodies may have 
a direct, destructive effect on the 
Tat protein. 
Much remains to be learned about 
the significance and function of the 
anti-Tat antibodies. But if they do 
prove to be a factor in delaying the 
progression to AIDS, their effects 
might eventually be boosted or mim­
icked to keep people who are infect­
ed with HIV asymptomatic for a 
longer time. 
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Defensive Maneuvers: The Search for a Vaccine 
Researchers in the Fischetti lab are exploring a novel approach for a 
vaccine that homes in on sites vvhere HIV first enters the body 
Professor Vincent Fischetti and 
Postdoctoral Associate Donata Medaglini 
are setting their sights on a vaccine that 
elicits mucosal immunity. T welve years into the AIDS epidemic, there is still no vac­cine against the disease. So far, 
most vaccine research has been 
geared toward boosting defensive 
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Most vaccine research has 
been geared toward boost­
ing defensive strategies 
that fight HIV once it has 
entered the body. But a 
different approach aims to 
prevent infection with the 
virus from occurring 
in the first place. 
strategies that fight HIV 
once it has entered the 
body. But Vincent Fischetti 
and his colleagues are tak­
ing a different approach. 
"We're targeting how to 
prevent the infection from 
occurring in the first place," 
he says. 
The researchers have 
their sights set on eliciting 
a type of response called 
mucosal immunity. The 
mucosal surfaces lining 
body cavities such as the 
mouth, gut, and genital 
tract provide one of the 
body's first lines of 
defense. Among the pro­
tective factors found there are spe­
cialized antibodies, known as IgA 
antibodies, whose functions-though 
still incompletely known-are 
believed to include preventing 
pathogens from attaching to cells. 
Such attachment is one of the first 
steps in infection. 
For many years, researchers 
believed that a mucosal response ini­
tiated at one site-say, by s�:allow­
ing an oral vaccine-would provide 
equally good protection at all mucos­
a! surfaces, since the cells that pro­
duce IgA antibodies travel from one 
mucosal site to another in the body. 
But Fischetti and others have shown 
that antibody response is strongest at 
the site where it is initially evoked. 
These findings are essential to 
work in Fischetti's lab, where one of 
the goals is to devise live vaccine 
vectors, or delivery systems, that 
home in on the sites where a 
pathogen first gains entry. These 
sites vary, depending on the 
pathogen. 
The roots of Fischetti's research 
stretch back to studies conducted by 
Rockefeller investigator Rebecca 
Lancefield in the first half of the cen­
tury. In a monumental achievement, 
she classified the multifarious strains, 
or serotypes, of streptococci, a type 
of gram-positive bacteria that cause a 
wide range of diseases in humans 
and animals. (Gram-positive bacteria 
are a subset of microorganisms that 
include the streptococci, staphylo­
cocci, and pneumococci.) 
As part of her work on "Group 
A" streptococci, Lancefield discov­
ered the M protein, a protein on the 
bacterium's surface that contributes 
to its ability to cause disease. Over 
the years, more than eighty different 
forms of the M protein have been 
found among the various strains of 
Group A strep. 
Fischetti and his co-workers ana­
lyzed the entire genetic and protein 
structure of a number of different M 
proteins. "By now, more is probably 
known about this molecule than 
about any other surface protein on 
any other gram-positive bacterium," 
he says. For instance, the Rockefeller 
researchers have learned that 
although most regions of the M pro­
tein vary among serotypes, some 
regions are identical, or conserved. 
One such conserved region is not 
only identical among all M proteins, 
but also among nearly all the surface 
proteins of gram�positive bacteria. 
This conserved region is responsible 
for firmly attaching surface proteins 
to the bacterial wall. 
The implications of this discovery 
are exciting. Using genetic engineer­
ing techniques, it should now be 
possible to fuse the conserved 
attachment region onto virtually any 
protein or protein fragment, and 
then prompt that fusion protein to 
become attached to the surface of 
any gram-positive bacterium. 
By exploiting harmless bacteria 
that are normally found on specific 
mucous membrane sites in the 
human body, the engineered pro­
teins could then be delivered exactly 
where they are needed. Once at the 
site, the proteins would provoke the 
production of antibodies that would 
Iater help protect against infection by 
the pathogen that normally carries 
these proteins. 
In collaboration with Italian 
researcher Gianni Pozzi (a former 
visiting professor at Rockefeller), 
Fischetti and his colleagues have 
already linked a number of geneti­
cally engineered proteins to a harm­
less bacterium found in the mouth, 
where it has evoked a strong anti­
body response when given orally to 
animals. Among those proteins' is 
HIV's gp120 protein, which plays a 
central role in the virus's ability to 
link up with and infect host cells. 
(See illustration, page 14.) 
The scientists are now starting 
experiments to attach gp120 to a 
harmless bacterium normally found 
in the vagina. They believe this strat­
egy will prove particularly useful for 
a vaccine against AIDS, since sexual 
contacts are the leading cause world­
wide of the transmission of HIV. 
Because the bacteria carrying the 
vaccine are live and continue to 
propagate, one-time vaccination of 
difficult-to-reach populations (such 
as those in Asia and Africa) would 
be possible. Moreover, the engi­
neered, live bacteria would be trans­
mitted through sexual contact to 
those not originally vaccinated. 
The res�archers' previous studies 
have made them hopeful that the 
vaginal vaccine will evoke not only a 
strong mucosal immune response, 
but also a strong systemic immune 
response-one that induces the pro­
duction of antibodies, known as IgG 
antibodies, that travel throughout the 
entire body via the blood. This "mul­
tiple warhead" approach may prove 
to be a real boon, given the unlikeli­
hood that a mucosal immune 
response will be able to prevent 
every single viral particle from enter­
ing the body. 
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Spelling Disaster: The Readout of HIV's Genetic Code 
Studies in the Roeder lab focus on the first step in the process that decodes 
information stored in the genes. That step is especially complex for HIV 
V iruses differ from bacterial, plant, and animal cells in countless ways. But in one 
fundamental respect, these entities­
considered by some to be less than 
alive-are identical to the most com­
p lex living cells in existence: the 
instructions encoded in their genes 
must be transformed into the pro­
teins that allow them to function. For 
HIV, those proteins include the 
structural proteins that shelter the 
virus's genes, the envelope proteins 
that help it invade human cells, and 
the catalytic proteins essential for 
many events throughout its life cycle. 
HIV's genetic instructions are car­
ried in RNA rather than DNA. An 
enzyme called reverse transcriptase 
copies the RNA genes into DNA, 
which is then integrated as so-called 
"proviral DNA" into the DNA of the 
host cell (see illustration, page 18). 
Once integrated, the proviral DNA 
can be transmuted into protein using 
the cell's own machinery. The nrst 
step in this process is transcription­
the readout of DNA into a molecular 
intermediate called messenger RNA 
(mRNA), whose information is then 
"translated" into protein. 
Transcription-an astoundingly 
complex process-involves the inter­
action of many proteins with one 
another and with DNA control ele­
ments located on the genes them­
selves. Rockefeller investigator 
Robert Roeder's pioneering research 
has already elucidated many of the 
molecular interactions that regulate 
the complex process of transcription, 
and he continues to break new 
ground in understanding the tran­
scription of many cellular and viral 
genes, including the genes of HIV. 
As part of his studies of HIV gene 
regulation, Roeder and his col­
leagues are investigating the function 
of a protein called Tat. 
Tat is a "transcription factor," a 
type of protein that plays a major 
role in the complex interactions 
involved in transcription. Like all 
other proteins, the instructions for 
transcription factors are encoded by 
the genes themselves. As is the case 
for all viruses, HIV gene transcription 
involves some transcription factors 
encoded by cellular genes, and oth­
ers encoded by genes of the virus. 
Tat is a virally encoded transcription 
factor. 
A number of cell-encoded tran­
scription factors can prompt HIV's 
genes to be transcribed at a low 
level. But Tat is required for high 
levels of transcription. Once the first 
rounds of HIV gene transcription 
result in the production of enough 
Tat protein, HIV transcription is 
enhanced several hundred times. 
Tat exerts its effects through a 
highly unusual mechanism-one so 
far seen only in the subset of retro­
viruses (called lentiviruses) to which 
HIV belongs. Tat interacts not with 
HIV's DNA genes, but rather with 
one of the very first mRNA regions 
to be transcribed from that DNA. 
This mRNA doubles back on itself to 
form a "hairpin" structure, called 
TAR, to which the Tat protein binds. 
Cellular factors also must bind to 
TAR in order for this "transactiva­
tion" to work. 
Exactly how all these molecular 
interactions enhance the transcrip-
tion of HIV genes is still a matter of 
much debate. Roeder and his col­
leagues believe 
that Tat's interac-
tion with TAR 
affects both the 
rate at which tran­
scription is initiat­
ed, and the effi­
ciency with which 
it continues along 
the entire length of 
HIV's genes. Re­
searchers in the lab 
are continuing to 
tease out the 
details of how Tat-
TAR interactions 
enhance HIV tran­
scription. If such 
interactions could 
be blocked, the 
transcription of 
The instructions in 
HIV's genes must be 
transformed into the 
proteins that allow the 
virus to function. 
Blocking the readout of 
those instructions could 
limit production of the 
substances the virus 
needs to survive. 
HIV genes would be dramatically 
limited-and so, therefore, would 
the production of the proteins HIV 
needs to survive. 
A Deadly Connection: AIDS and Drug Abuse 
Researchers at Rockefeller vvere among the first to vievv drug addiction 
as a physical disease. Today, researchers in the Kreek lab explore 
treatment for addiction, and aim to understand its biological basis 
D
rug addiction is a major factor 
fueling the AIDS epidemic. By 
sharing needles, HIV-infected 
drug users pass their infection to 
others; in addition, addicts often 
engage in unsafe sexual practices 
that can also lead to infection. The 
result of all these high-risk activities 
is grimly evident in the statistics. In 
New York City, for instance, intra­
venous drug use is the cause of 
almost half the AIDS cases reported, 
and more than 85 percent of chil­
dren with AIDS were infected due to 
their parents' drug use. 
How can this deadly connection 
be broken? One way is through 
effective treatment for drug abuse. 
As Rockefeller investigator Mary 
Jeanne Kreek explains, "With any 
epidemic, you must remove the 
Professor Robert Roeder (left) and 
Postdoctoral Fellow Camilo Parada study 
the complicated molecula( interactions 
controlling the readout of HIV's genes. 
source of infection, and a major 
source of infection in AIDS is the 
drug addict. That is why treatment to 
end addiction is essential, both to 
treat the individual, and to prevent 
him or her from infecting others." 
The treatment of drug addiction 
has a long history at Rockefeller, 
reaching back over thirty years to 
the pioneering work of Professor 
Emeritus Vincent Dole. Dole, the late 
Marie Nyswander, and Kreek were 
among the few at that time who 
viewed the drug addict not as an 
unsalvageable criminal but as a per­
son afflicted by a physical disease. 
Their groundbreaking research 
showed that heroin addicts could be 
successfully treated with methadone, 
a long-acting opiate. As a result of 
these studies, hundreds of 
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Guest Investigator Lisa Borg (lefrj, Associate Professor Mary Jeanne Kreek (centei), and Senior Research 
Associate Ann Ho study the immune responses of drug addicts in treatment versus those not in treatment. 
methadone maintenance programs 
were established worldwide. 
The Rockefeller tradition of 
addiction treat­
ment and research 
Drug addiction is a major 
factor fueling the AIDS 
epidemic. Treatment to 
end addiction is essential, 
both to treat the 
individual and to pre­
vent him or her from 
infecting others. 
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continues today in 
the lab headed by 
Kreek, which is a 
National Institutes 
of Health-National 
Institute of Drug 
Abuse Center for 
Research in Addic­
tion. Much of that 
work has a direct 
bearing on AIDS. 
For instance, using 
blood serum sam­
ples collected and 
stored as part of a 
study conducted at Rockefeller, 
Kreek and her colleagues were the 
first to trace the advent of the HIV 
epidemic among drug abusers in 
New York City back to 1978. The 
scientists have also documented the 
effects of methadone maintenance 
on HIV infection in heroin addicts. 
Their 1984 studies, which have been 
confirmed by other labs, showed a 
dramatic impact: while approximate­
ly 50 percent of hard-core heroin 
addicts were HIV positive, only 9 
percent of methadone-maintained 
addicts tested positive-and those 
were people who continued to use 
cocaine intravenously. 
The concept of methadone main­
tenance programs has often met with 
resistance, but Kreek is optimistic 
that the tide is now turning. "The 
AIDS epidemic has made the world 
awaken to the need for effective 
pharmacologic treatment of heroin 
addiction," she says. "For the first 
time, people are really willing to see 
that methadone maintenance works." 
In addition to their research on 
methadone maintenance, Kreek and 
her colleagues are examining other 
links between AIDS and drug use, an 
approach that falls naturally into 
their studies of the biological bases 
of addiction. One of the lab's main 
goals is to learn why some people 
who are exposed to a substance 
become addicted, while others do 
not. Says Kreek, "Provocative evi­
dence suggests that there may be 
inherent vulnerabilities to many 
types of dependencies." For instance, 
research in the lab has shown that 
addiction not only to heroin, but to 
cocaine and alcohol as well, may 
involve perturbations in the endoge­
nous opioid system. The endoge­
nous opioids are a class of peptides, 
or short amino acids, that are pro­
duced in the brain and that play 
roles in reproduction and the stress 
response. 
Endogenous opioids also are 
involved in the complex biochemical 
pathways that affect immune func­
tion. Kreek and her colleagues have 
been examining the immune-system 
effects of drug use in HIV-negative 
heroin addicts. Their results show 
that untreated heroin addicts have 
abnormalities in many immune-sys­
tem parameters, such as natural killer 
cell activity, T cell counts, and anti­
body levels. These abnormalities dis­
appear, however, when the addicts 
are successfully treated with 
methadone. 
Such findings may help explain 
why AIDS often progresses rapidly 
in untreated heroin addicts who 
become infected with HIV. They 
also underline the need to make 
methadone treatment available 
for all heroin addicts-including 
those infected with HIV-to bolster 
their immune systems as much as 
possible. 
On the Trail of Disease: Tracking 1 Emerging Viruses 1
Research by Stephen Morse explores 1emerging viruses1-viruses1 such as 
HIV# that seemingly strike out of nowhere. Better surveillance 
is needed to prevent the spread of such viruses 
A decade ago, the world had barely heard of HIV. Now, at least fifteen million people 
are infected with the virus, and two 
and a half million have already died 
from the syndrome it causes. Where 
did HIV come from? How did it 
spread so fast? Are there other 
viruses like HIV out there just wait­
ing to strike? These are some of the 
questions that interest Rockefeller 
investigator Stephen Morse. 
Morse, a virologist, devotes much 
of his research energies to the study 
of the mouse thymic virus, a rodent 
virus that shares a number of similar­
ities with HIV, including its ability to 
deplete CD4 T cells. But along with 
his laboratory studies of how this 
one particular virus acts on the mole­
cular level, Morse is also pursuing 
viruses in a broader context. His 
quarry are "emerging viruses"-virus­
es, such as HIV, that seemingly strike 
out of nowhere. 
His interest in emerging viruses 
grew out of a chance conversation 
held in the late 1980s with Joshua 
Lederberg, the Nobel Prize-winning 
scientist who was then Rockefeller's 
president. At a faculty gathering, 
Lederberg asked Morse about the 
potential dangers a particular mouse 
virus might pose for researchers 
working with lab rodents. This initial 
question grew into an interest so 
deep that, soon after, Morse led a 
multidisciplinary conference on 
emerging viruses at the National 
Institutes of Health. That conference 
seeded the growth of a new consen­
sus about how emerging viruses 
make their mark on the world. 
Most experts now agree that new 
viruses do not often emerge as the 
result of rapid mutations that quickly 
transform relatively benign viruses 
into dangerous ones. "Usually, 
emerging viruses are simply existing 
infections that have been introduced 
from an animal population into a 
human one," Morse explains. When, 
for any number of reasons, the new 
human host is unable to combat the 
virus, the disease can rapidly 
become an epidemic, which is 
spread by the complex behaviors of 
humans. 
Take the case of HIV-2, the v;iral 
strain that causes the majority of 
AIDS cases in West Africa. The 
genetic makeup of HIV-2 is virtually 
identical to a monkey virus called 
SIV. For many decades, humans in 
West Africa have probably occasion­
ally been infected with SIV, due to 
their practices of eating monkey 
meat and keeping monkeys as pets. 
But demographic changes-moves to 
crowded urban centers, increases in 
the number of sexual partners, wider 
travel, and adoption of modern med­
ical practices such as the use of nee­
dles-all contributed to a hastening 
spread of the disease in the last 
quarter of the twentieth century. The 
origin of HIV-1 (the most common 
cause of AIDS in Europe and the 
United States) is less clear, but many 
researchers believe that some other 
infection of primates (perhaps chim­
panzees) is the root cause. 
Much can be done to prevent the 
spread of viral disease, if the factors 
contributing to viral emergence can 
be monitored. Indeed, the need for 
dramatically improved global surveil­
lance was stressed by a recent report 
on emerging infections sponsored by 
the National Academy of Science's 
Institute of Medicine. Morse, who 
helped write the report, is now 
spearheading efforts to implement its 
recommendations. 
His concern for tracking and sur­
veillance of emerging viruses also 
underlies the collaborative research 
he is conducting with researchers 
elsewhere, such as Jeffrey Laurence 
of the Cornell University Medical 
College, and Irwin Gelman, a former 
Rockefeller postdoctoral fellow who 
is now a faculty member at  the 
Mount Sinai Medical Center. These 
scientists were among the co-authors 
of the paper that caused an interna­
tional sensation during the summer 
of 1992. The paper described the dis­
covery of a small number of individ­
uals with "AIDS-defining" illnesses­
for instance, opportunistic infections ,
in persons with low CD4 T cell 
counts-that could not be attributed 
to HIV identified by any test current-
ly in use. 
The researchers' report attracted 
tremendous media interest. So did a 
number of papers, published about 
six months later, that disputed the 
idea of an "HIV-negative" AIDS. 
While the press's attention to this 
issue has now died down, the com­
mitment of Morse and his colleagues 
HIV-2, the causative virus of most cases of 
AIDS in West Africa, is virtually identical to 
SIV, a virus found in monkeys such as this 
house pet. 
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Assistant Professor Stephen Morse (right) 
and Assistant for Research James Sullivan 
use highly sensitive assays to study the viral 
"family" to which HIV belongs. 
to further investigate the subject has 
not. The scientists have been using 
assays developed at Rockefeller by 
Morse and Gelman that can detect 
genetic sequences from all viruses in 
"Emerging viruses" such as 
HIV are usually existing 
infections that have been 
introduced from an animal 
population into a human 
one. The disease can then 
rapidly become epidemic 
when spread by the com­
p I ex behaviors of humans. 
the lentivirus subfamily, the class of 
retroviruses to which HIV belongs. 
The researchers believe they may 
have found evidence of such gene 
sequences in the blood of persons 
with "HIV-negative" AIDS, and that 
these patients' cases may represent 
infection with a variant of HIV-1 that 
less sensitive tests have failed to 
identify. 
"These findings are not as strange 
or lt:!rid as some of the initial press 
reports suggested," says Morse. 
"Given the rapid mutation rate of 
HIV, new variants are bound to arise, 
and it seems likely that some may be 
different enough to escape detection 
by tests currently in use." Noting that 
only a handful of cases have so far 
been reported, he says, "If there is a 
variant of HIV-1, its impact has clear­
ly been far less dramatic than that 
of the well-recognized HIV-1." 
Nonetheless, Morse believes further 
research into this controversial ques­
tion must continue, so that tests can 
be refined if necessary to help pre­
vent the spread of AIDS. 
Conclusion 
Research Provides 
Hope for Future 
AIDS is a worldwide catastrophe 
whose toll will only worsen unless 
ways are found to better treat it, pre­
vent it, and, ultimately cure it. Until 
such discoveries are made, millions 
will continue to die from the disease 
-often, tragically, while they are still
in the prime of life.
Many mysteries remain about 
AIDS, and creative new approaches 
are required to solve them. Perhaps 
no institution is better poised to fos­
ter such creative solutions than The 
Rockefeller University. Founded 
to conquer infectious diseases, 
Rockefeller has always encouraged 
interdisciplinary research that tran­
scends rigidly defined scientific cate­
gories in the quest to improve 
human health. Today, Rockefeller 
researchers are drawing on their his­
toric expertise in a wide range of 
fields such as molecular biology, 
virology, immunology, and infectious 
disease to meet the enormous scien­
tific challenges posed by AIDS. At 
the heart of much of their work is 
The Rockefeller University Hospital, 
a unique facility where insights 
gained through basic biomedical 
research can be brought to bear on 
the treatment of people infected 
with HIV. 
Just as research about AIDS 
draws on multiple disciplines, so the 
results of that research promise to 
shed new light on numerous scientif­
ic fields. Because HIV thrives by 
hijacking and subverting many nor­
mal cellular functions, research into 
the virus's modus operandi of neces­
sity explores some of biology's most 
fundamental questions, such as how 
immune responses are generated 
and how the readout of genes is 
controlled. The results of this explo­
ration promise new insight into 
many diseases, including cancer and 
autoimmune disease. 
But the basic goal of AIDS 
research is, of course, to conquer 
AIDS. Drawing on their tradition of 
research "Pro Bono Humani 
Generi s"-for the good of  
humankind-scientists at Rockefeller 
are aiming their sights at this goal. 
Over the years, AIDS-related research at 
the university has been supported by a 
number of individuals, foundations, 
and corporations, including Alexander 
and Helene Abraham (through the 
Jacob Bleibtreu Foundation, Inc.), The 
Cremona Fund Inc., The Aaron 
Diamond Foundation, The Irvington 
Institute for Medical Research, the Abby 
R. Mauze Charitable Trust, the Fannie
E. Rippel Foundation, The Starr
Foundation, and the Harry Winston
Research Foundation, Inc. Significant
support has also been provided by the
federal government through the National
Institutes of Health.
., 
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This world map illustrates 
the large portion of the 
globe in which malaria is 
commonly transmitted. 
Scientists at Rockefeller 
Advance in Struggle Against 
M 
alaria now affects a staggering 3 00 million peo­
ple. Over one million, mostly children, die 
from the disease every year. Others suffer from 
chronic, debilitating malarial attacks, characterized by 
fevers, chills, and violent shaking. While AIDS first 
appeared in the 1980s, malaria has plagued the popula­
tion of tropical regions for centuries. Today, malaria 
is still counted among the world's deadliest diseases 
and leading public health problems. Recently it has 
Malaria now affects a 
staggering 300 mil­
lion people. Over one 
million, mostly chil­
dren, die from the 
disease· every year. 
become even more intractable due to the 
development of drug-resistant strains of 
the disease. 
Scientists at The Rockefeller Univer­
sity have contributed a great deal to the 
understanding of malaria, which is caused 
by a parasite spread from person to person 
via mosquitoes. Over the last fifty years, 
Rockefeller scientists have tested new anti­
malarial drugs, investigated the parasite's 
life cycle, discovered groundbreaking new 
research methods, and worked on the devel­
opment of an experimental vaccine. This work may ulti­
mately help save countless lives. 
World War II: Malaria Research 
for Their Country 
Parasitologist William Trager arrived at 
Rockefeller in 1933 after graduating with a doctorate 
from Harvard University. In his initial studies of malar­
ia, he provided the first direct evidence that lack of cer­
tain nutrients increases susceptibility to the illness. He 
Mika Ono Benedyk is a writer and editor in The 
Rockefeller University Public Affairs Office. 
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had just begun this work, however, when World War II 
broke out. 
The U.S. Army was in desperate need of specialists 
in malaria, as the disease threatened to incapacitate 
American troops posted in the South Pacific. To make 
matters worse, the Japanese controlled supplies of qui­
nine, the drug of choice at that time, which 
was harvested from cinchona tree plantations in 
parts of Asia. 
Trager and two of his Rockefeller colleagues, virol­
ogist Frederick Bang and parasitologist Malcolm 
Ferguson, enlisted. They were posted in a special med­
ical unit in Australia whose mission was to test a new 
antimalarial drug. The drug, called Atabrine, was devel­
oped by the Germans in 1932. Preliminary work by the 
U.S. Army suggested that Atabrine could be used safely 
as a suppressant drug. 
Members of this unit administered Atabrine to 
malaria sufferers in the recommended dosages-one 
tablet a day, six days a week-and followed the patients' 
blood levels. The first subjects, men who had been 
fighting in New Guinea, were having an average of four 
attacks of malaria per year. Atabrine stopped the attacks 
completely. Further trials in Rockhampton with hun­
dreds of men confirmed that the drug was a remarkably 
effective one: as long as the soldiers took Atabrine, they 
didn't have malarial attacks; if they stopped, symptoms 
would return within a few weeks. 
"One of the young men we treated in the first trials 
had had some dozen attacks of malaria," said Trager. 
"He was in such bad shape when we first saw him that 
he needed a blood transfusion. With the help of 
Atabrine he recovered and became a technician with us. 
With his cooperation, we then did a little experiment. 
We asked him to stop taking his Atabrine. Like clock­
work, the parasites came back. We could find them in 
the blood before he had any symptoms." 
On the basis of this and other work, the suppres­
sant Atabrine became the standard army requirement in 
malarious regions, especially the Southwest Pacific. 
According to Trager, one of the medics later said that 
they had never had such a healthy army as in New 
Guinea at the time. 
While Atabrine was critical for American troops in 
World War II, it did have one drawback that prevented 
forty-eight hours-to develop fully. By that time, it has 
produced about a dozen daughter parasites (called 
merozoites in this stage) which then break out of the 
cell to invade others. 
Working with samples of the malaria parasite that 
Trager personally brought back from Liberia, Trager 
and Rudzinska found that about half way through this 
cycle in the red blood cell, the cells develop knob-like 
structures on their membranes. Further biochemical 
work in the lab with Araxie Kilejian and Michael 
Wallach helped show that these structures are partially 
made up of a parasite-derived protein that is integrated 
into the host cell. 
It turns out that the lab had identified the struc-
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it from being widely used afterwards. "One reason it 
works so well is that it tends to accumulate in the tis­
sue," explained Trager. "It is a yellow-colored drug 
with a beautiful green fluorescence. After a couple of 
weeks of taking it and from then on, army personnel 
developed what was known as an 'Atabrine tan.' The 
skin had a peculiar yellow color, and in the sunshine, 
people's ears showed a green fluorescence. Of course, 
they didn't like that." 
Electron Microscopy Reveals 
New World 
After the war, Trager returned to Rockefeller to 
continue his studies of bird malaria. A few years later, 
he was joined by Maria Rudzinska, a protozoologist 
who was the first to apply the newly developed electron 
microscope to the study of the malaria parasite. 
Rudzinska's work immediately revealed a whole 
new world. Long-standing mysteries such as how the 
parasite feeds on red blood cells were suddenly solved 
with ease. Although the fixation for the slides at that 
time often revealed nothing but big holes, she was able 
to see the parasite clearly the first time she tried. "In the 
very first sample I looked at, I made a real discovery," 
Rudzinska said. "I could see the parasite engulfing big 
pieces of the red blood cell. I could see inside the food 
vacuole. It was a thrilling experience." 
Electron microscopy also allowed Trager and 
Rudzinska to understand how the malaria parasite 
develops within the red blood cell. After invading the 
cell, the parasite takes about two days-forty-four to 
Rockefeller University parasitologist William Trager won worldwide 
acclaim for his work on malaria, most notably for his discovery of a 
method to culture the disease-causing parasite. He is shown here 
with a statuette he received as the first recipient of the 
Rameshwardas Birla Triennial International Award for outstanding 
contributions to the field of tropical diseases. 
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rnres that are responsible for much of the pathology of 
severe malaria. The knoblike protrusions adhere to the 
walls of capillaries in various organs, causing organ 
damage. In the most serious cases, they may block capil­
laries in the brain, causing cerebral malaria, which is 
often fatal. 
In very recent work, Dr. Irwin Sherman of the 
University of California at Riverside, who was a post­
doctoral fellow with Trager in the 1960s and who has 
since become a leading authority on the biochemistry of 
malaria parasites, has synthesized specific peptides that 
interfere with this adhesion. These may provide thera­
py for cerebral malaria. 
Cultivation: A Major Breakthrough 
In the early 1970s, the most significant roadbloc}c 
to developing a malaria vaccine was the lack of any 
means to culrnre the parasite. 
Scientists were limited to 
Most researchers in 
the field are now 
optimistic that there 
will be a malaria vac-
cine in the future. 
working with mice, birds or 
monkeys-an expensive as well 
as imperfect undertaking, as 
these strains of malaria differ 
from those that infect humans. 
Many sci en tis ts around the 
world struggled to grow the 
red blood cell stage of the_ par­
asite in culrnre. 
In 1976, Trager and his colleague James Jensen 
succeeded. "Many people were trying to grow the para­
sites in agitated culrnres," Trager said. "I thought that 
since the affected cells are attached to the walls of the 
capillaries half of the time, they are used to sitting qui­
etly. So, instead of using an agitated culrnre, we created 
a device where a medium flowed slowly over a settled 
layer of red blood cells. Strangely enough, 
it worked!" 
The finding generated a great deal of excitement. 
Trager and Jensen's method, which is still used today, 
gave scientists a simple way to work with the malaria 
parasite in the lab. Trager soon received many awards 
for his work, including the Darling Medal and Prize of 
the World Health Organization, the First 
Rameshwardas Birla Triennial International Award of 
the Medical Research Centre of the Bombay Hospital 
Trust, the Leukart Medal of the German Society for 
Parasitology, and the Manson Medal of the Royal 
Society of Tropical Medicine and Hygiene. 
The new culrnre method opened up a host of new 
research possibilities. It allowed the study of malarial 
drug resistance (most notably to chloroquine, a cheap 
and relatively safe drug widely used to combat the dis-
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ease) and research into drugs that may negate this resis­
tance. Some notable contributors in this area have 
included Trager and one-time members of his lab, 
including biochemist Bill Scheibe! (now at the 
Uniformed Services University of the Health Sciences 
in Bethesda, Maryland) and scientist Virendra Bhasin 
(now at the University of Delhi, India). 
The culrnre method also made possible a deeper 
understanding of the protective effect against malaria of 
the sickle hemoglobin mutation. Milton Friedman, one 
of Trager's srndents, found that malaria parasites could 
not develop. normally in red blood cells carrying the 
sickle cell trait when these cells were exposed to rela­
tively low oxygen tension such as occurs in many organs 
of the body in people with the condition. This helps 
explain why people with the sickle cell trait rarely suffer 
from severe malaria. Malaria has supplied the evolution­
ary pressure that has maintained the high prevalence of 
this otherwise deleterious mutation in West Africa. 
More recently, the culrnre method has facilitated 
basic work using newly developed molecular techniques 
on the genetics of the malaria parasite. Rockefeller 
alumnus Jeffrey Ravetch, now at Memorial Sloan­
Kettering Cancer Instirnte, is one of those at the fore­
front of these srndies. 
As hoped, the ability to culrnre the parasite has also 
been invaluable in making progress toward developing 
a vaccine. 
Toward a Vaccine 
Rockefeller investigator Margaret Perkins, a former 
fellow in the Trager lab, is conducting research that 
may be directly applied to a future vaccine against 
malaria. Examining the biochemistry of the organism, 
Perkins has identified several proteins on the parasite's 
surface that enable it to bind to, and enter, the 
red blood cell, as well as several other proteins that 
are secreted into the host cell membrane, facilitating 
mvas1on. 
The hope is that some of these proteins-or impor­
tant pieces of them-can be synthesized and used in a 
vaccine to stimulate the immune system against the par­
asite before it causes disease. One of the proteins 
Perkins identified, MSP 1, may be tested as early as next 
year in human trials. If it proves successful, it will prob­
ably be used in combination with other immune-stimu­
lating antigens from different stages of the parasite. 
These will most likely include other proteins from the 
merozoite stage, the form that invades the red blood 
cell. Proteins from the sporozoite stage, the form that 
travels from the site of the mosquito bite to the liver, 
and the sexual stages that develop while the parasite is 
within the mosquito will probably also be included. 
"It had been hoped that a vaccine against the 
sporozoite would be sufficient to stop development of 
subsequent stages in humans, as this would be interven­
tion at the first point," said Perkins. "Unfortunately, we 
now realize that this is too simplistic. Escape of a few 
sporozoites from the liver will result in infection. The 
idea now is to develop a multiunit vaccine, made up of 
antigens or pieces of antigens from all stages of the par­
asite. This would block the parasite at each stage of 
development. 
"Most researchers in the field are now optimistic 
that there will be a malaria vaccine in the future," she 
continued. "People who live in endemic areas do 
develop partial immunity when they reach adulthood. 
This suggests that there is hope that vaccine-induced 
immunity will be successful. It will be a matter of trial 
and error to determine which combination of antigens 
will work. Children are most at risk, so the most 
important vaccine to develop is one that is effective in 
early childhood." 
Clinical Trials 
While work continues on potential vaccine com­
ponents, one experimental vaccine, developed by a 
Rockefeller adjunct faculty member, Manuel E. 
Patarroyo, has come far enough along to be tested in 
clinical trials. 
Patarroyo, now head of the Institute of 
Immunology of the San Juan de Dios Hospital in his 
native Colombia, took a unique approach to making 
the vaccine. Virtually all vaccines to date, including 
those for polio, mumps, measles, and rubella, have been 
fashioned from mutated disease microbes. Instead, 
Patarroyo's vaccine is synthetic, consisting of four pep­
tides (protein segments)-three from the merozoite 
stage of the parasite and one from the sporozoite 
stage-fused into a large molecule. 
Patarroyo learned many of the techniques he 
applied to creating the vaccine at Rockefeller, from sci­
entists such as immunologist Henry Kunkel, microbiol­
ogist John Zabriskie, and protein chemist Bruce 
Merrifield. 
"If Patarroyo's vaccine turns out to be a successful 
one, it will be a good example of the kind of develop­
ment that should happen more often," said Trager, who 
at age eighty-three is still active in his lab. "The basic 
work, namely the cultivating of the parasites and the 
peptide synthesis, was done at Rockefeller, and the 
putting together of a practical application was done in 
the country where it was needed." 
Preliminary tests of Patarroyo's vaccine in Brazil, 
Colombia, Ecuador, Venezuela, and Tanzania are 
promising. "We are getting 40 to 66 percent protection 
in field trials," said Patarroyo, whose work recently has 
received a great deal of publicity. 
Another advantage of the vaccine is that it is cheap. 
A three-dose series �osts thirty cents, "less than the 
price of a Coca-Cola," Patarroyo noted. Even less 
developed countries may be able to afford mass immu­
nization if the vaccine proves feasible. 
Although Patarroyo's vaccine will not eliminate 
malaria, it may prove to be one important victory in 
humankind's long war against infectious disease. 
Margaret Perkins, a Rockefeller University investi­
gator, is conducting research which may be directly 
applied to a future vaccine against malaria. 
1993 
Above, Jules Hirsch, pro­
fessor and physician-in­
chief, stands in front of a 
portrait of Rufus Cole, 
the first physician-in­
chief of the hospital. 
Hirsch directs a laborato­
ry that studies energy 
metabolism in man. 
1923 
Right, Rockefeller 
investigator Michael 
Heidelberger (left) and an 
unidentified technician 
work in the laboratory of 
Donald Van Slyke. Van 
Slyke brought a chemical 
approach to the study of 
human disease. 
THE ROCKEFELLE R 
UNIVERSITY HOSPITAL: 
DECADFS 
OF ·PATIENT-
ORIENTED RESEARCH 
T he Rockefeller University Hospital, founded in 1910 as the first clinical research center in the country, 
pioneered a new kind of medical research in the United 
States. Rather than serving simply as a testing site for 
ideas generated in the lab, physicians were free to pursue 
experiments on the fundamental roots of disease. Over 
the last eight decades, the pioneering research that has 
come out of The Rockefeller University Hospital has 
included the discovery that genetic material is made of 
DNA, the isolation and testing of natural antibodies, the 
identification of specific genetic defects associated with 
atherosclerosis, and the development of a highly effective 
meningitis vaccine now used worldwide. 
All photos are courtesy of The Rockefeller University Archives or Robert Reichert. 
1992 
Left, Professor Jan 
Breslow (right) and 
Postdoctoral Associate 
Andrew Plump conduct­
ed research that resulted 
in the first transgenic 
mouse model of athero­
sclerosis, a major break­
through in the study of 
this lethal disease. 
1992 
Left, The late 
Professor and Senior 
Physician D. Martin 
Carter and Nurse 
Dorothea Caldwell­
Brown speak with a 
young patient. Carter 
was a leading expert in 
clinical and experimen­
tal dermatology. 
1922 
Below, Rufus Cole, 
who was physician-in­
chief from 1910 to 
1937, stands at the 
bedside of one of the 
hospital's patients. 
Cole led important 
studies on the nature of 
acute lobar pneumo­
nia, then one of the 
nation's leading killers. 
. .... 
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e.1920
Right, William C. 
Stadie, a Rockefeller 
investigator, devel­
oped a new and far 
more effective way to 
administer oxygen to 
pneumonia patients. 
This special chamber 
enabled patients to 
breathe a regulated 
concentration of oxy­
gen, greatly relieving 
their respiratory dis­
tress. 
1918 
Below, Rockefeller 
investigator and 
Nobel laureate Alexis 
Carrel demonstrates 
a new method for 
treating infected 
wounds. Carrel 
developed the proce­
dure with Henry 
Dakin during World 
War I, when infec­
tion was a serious 
problem in treating 
wounded soldiers at 
the front. 
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1993 
Left, Professor and 
Senior Physician 
Ralph Steinman and 
Associate Professor 
Gilla Kaplan work to 
elucidate the body's 
complex immune 
defense system which 
fights disease-causing 
microbes. 
1932 
Above, Oswald Avery ( center 
front) stands with some members 
from his lab. 
1993 
Left, The current scientists and 
staff of The Rock�f �ller 
University Hospital bring the 
most modern techniques to bear 
on a variety of important clinical 
problems. Today's research top­
ics include obesity, drug addic­
tion, tuberculosis, aging, menin­
gitis, strep, rheumatic fever, 
jaundice, psoriasis, wound heal­
ing, and AIDS. 
The· 
Double­
EdgedSword 
T by Susan BlumI he patients' cases were
highly unusual. All three had small-cell lung cancer, 
a deadly type of tumor that rapidly kills most of its 
victims and that almost never regresses, even with 
aggressive treatment. Yet-in some cases with thera­
py, in others without-these patients' tumors shrank 
or disappeared completely. Their good luck, though, 
was not unalloyed. Though their cancers resolved, 
the patients were plagued by an array of neurological 
symptoms, some so debilitating that they could no 
longer walk or feed themselves. 
Assistant Professor Robert Darnell recently 
reported on these cases in the British medical jour­
nal, The Lancet. They are examples of the family of 
rare disorders, known as paraneoplastic neurological 
syndromes, under study in his lab. Darnell, an M.D.­
Ph.D., says his research into the syndromes allows 
him to pursue his two compelling intellectual inter­
ests-gene regulation and neurobiology-and his 
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commitment to two scientific approaches-basic 
research and clinical investigation. 
As a graduate student at the Washington 
University School of Medicine in St. Louis, Darnell 
was intrigued by the mechanisms that control how 
and when genes are transcribed (or read out) and 
how their instructions are used to make proteins. 
This interest may 
Robert Darnell's have had a genetic
research explore$ 
an unusual immune 
response that 
attacks cancer cells 
but also wreaks 
havoc in the brain. 
component. Darnell's 
father, Professor
James E. Darnell, Jr., 
1s a Rockefeller 
University faculty 
member whose re­
search has elucidated 
some of the most
fundamental aspects 
of transcriptional 
control. 
Darnell explains 
that during the early 
1980s, when he was earning his M.D. and Ph.D. 
degrees, "studies were just starting to focus on onco­
genes, genes that play central roles in signaling a cell 
to differentiate or multiply in response to messages 
from its environment." When these genes are mutat­
ed, or when their regulation goes awry, cancer 
can result. 
Compelling as they were, the oncogene studies 
were not the only ones that attracted Darnell's inter­
est during his training. He was equally fascinated by 
research in neurobiology, which was starting to 
unravel the mechanisms by which neurons (nerve 
cells) change in response to signaling events. "It 
seemed to me that neurons and other cells in the 
body might both use the same kinds of signaling 
pathways for different purposes," he says. "For 
instance, in most cells, these signals normally culmi­
nate in regulated cell division, and their deregulation 
can lead to cancer. In neurons, which do not divide, 
Assistant Professor Robert Darnell inves­
tigates a rare family of disorders called 
the paraneoplastic neurological syn­
dromes. His studies may ultimately lead 
to strategies that boost the body's ability 
to fight cancer. 
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the functions Qf the signaling pathway are unknown, 
but are perhaps related to neurons' plasticity-their 
ability to change connections with other neurons in 
response to messages from their environment." 
To pursue the interconnections between neuro­
biology and cancer biology, and to conduct both 
basic research and clinical sqidies, Darnell became 
an attendi'ng' neurooncologist at Memorial 
Sloan-Kettering Cancer Center. There he worked 
with Jerome Posner, a pioneer in ,the study of para­
neoplastic neurologic syndromes�disorders that 
melded Darnell's two main 
interests. 
\� ' 
against them. Darnell believes that the vigor and suc­
cess of this defense supports the long-held p.otion 
that many incipient cancers are nipped i� the bud 
without our ever becoming aware that thi�y �ave 
occurred. 
But patients with paraneoplastic disease do 
become aware that they have (or had) cancer-usual­
ly not because of the cancer itself, but because of the 
immune response it elicits. For some reason-per­
haps a br�ak in the blood-brain barrier that normally 
. screens the_ brain from many substances-antibodiesto the onconeural protein gain 
access to brain cells. The 
In these ,diseases, small 
numbers of t�mor cells of a 
Studies of "out-of- result: degenerative neurologi­
cal diseases that, depending on 
the neurons involved, can 
impair balance, sight, motion, 
memory, and a host of other 
critical functions. 
particular type----'-say, tumors 
of the lung or· of the breast­
produce a protein normally 
made only by a particular type 
of nerve cell-say, a Purkinje 
cell in the region of the brain 
called the cerebellum. This 
protein production occurs due 
to the expression, or activa-
place" proteins 
promise insights into 
cancer, the brain, and Why are the onconeural 
proteins perceived as foreign? 
"The immune system proba­
bly doesn't work in the brain 
the immune system. 
tion, in the tumor cell of a gene normally turned on 
only in the nerve cell. 
The reason for this ectopic, or out-of-place, 
gene expression is not yet understood. Perhaps it is 
simply the random result of the cellular deregulation 
that is cancer's hallmark. But Darnell is investigating 
another possibility: that the ectopically expressed 
genes normally play important regulatory roles in 
nerve cells. Their aberra�t expression would give 
cancer cells an advantage over normal ones, allowing 
them to circumvent the controls imposed by their 
own signaling networks. Darnell has termed such 
genes onconeural genes. 
In the tumor, the proteins encoded by 
onconeural genes are perceived as foreign by the 
immune system, which mounts an �ffective attack 
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exactly the same way it does in 
. the rest of the body," Darnell speculates. Somehow, 
this difference prevents the immune system from 
- "learning" that the onconeural proteins belong to 
the self. Thus, the proteins provoke an immune 
response both in the tumor cells, where they do not 
occur normally, and subsequently in the nerve cells, 
where they are usually produced. 
Just as the immunologic rationale for the attack 
remains unknown, so does its mechanism. Do anti­
bodies alone orchestrate the attack against onconeur­
al proteins, or are immune cells known as cytotoxic 
T cells also involved? Darnell is conducting studies 
at The Rockefeller University Hospital to investi­
gate-and design ways to modulate-the immune 
attack in patients with paraneoplastic syndromes. 
Darnell is also exploring the syndromes 
by cloning (that is, isolating) the onconeural _genes __ 
and characterizing the proteips for which they code. · 
So far, five main types of genes h_ave been cloned,each one coding for a protein that was hitherto com­
pletely unknown. Darnell played a collaborative or 
leading role in the work on three of the genes and 
their products, and believes additional ones 
may yet be found. 
Many of the onconeural genes now character­
ized give suggestive support to the hypothesis that 
they play critical roles 
in cellular regulation 
and signaling. For 
instance, one gene 
codes for a Purkinje 
neuronal protein with 
the "leucine zipper" 
motifs characteristic of 
many proteins that 
regulate gene tran­
scription. Another 
gene codes for the first 
identified neuron-spe­
cific adaptin-a pro­
tein . that forms a 
bridge between clath-
rin, an! ·important cell-
s+urfafe protein, and 
the "taj}s" of receptors 
that transmit signals 
, • coming.from outside the cell. A third gene, charac-
terized, si�ce Darnell came to Rockefeller, codes for 
a pro�e�n expressed in the parts of the developing 
centr�l �e�ous syste� devoted to motor functions. 
Prelirpin;ry experimental result� indicate that this 
protein-plays a role after traJ?-�cription is completed, 
by.regulating the proGess· by �rhich newly transcribed 
genes get turned into proteinl. 
By inyestigating how on.coneural proteins func­
tion in signaling and regulqtory pathways, Darnell's 
work may yield insights into some of neurobiology's 
most basic questions. And by investigating how the 
immune system's response to these proteins can trig­
ger neuronal death, his research also holds promise 
for therapeutic advances on a number of fronts. 
Insights gained through the clinical studies at 
The Rockefeller University Hospital' may prove rek­
vant not only. to the paraneoplastic syndromes but 
to other autoimmune neurologic dis:eases such as 
multiple sclerosis. Moreover, the inv�stigations into 
how im�une system 
respo1:1ses can trigger 
neuronal death may 
ultimately shed light -· . 
on degen�rative dis­
eases in which cell 
death is triggered by 
mechanisms other 
than direct immune 
attack. 
Darnell's studies 
may also advance the 
fight against cancer. 
"The paraneoplastic 
syndromes identify 
bona fide tumor anti­
gens that are tar­
gets of an immune 
response," he says. 
Although other can­
cer cells express unusual antigens (cell surface pro­
teins), none described to date elicits a stro:tJ.g enough 
counterattack to thwart the cancer's $'rowth. Darnell 
is currently starting studies of breast tumors in 
mice-good animal models for cancer�to learn 
·. more about how onconeural protein�.,provoke such a
vigorous immune response. A bett�r • und�rstanding
of this process may ultimately lead· t0 strategies
that enhance the bo?y's ability to :��nd off a wider
range of cancers. I ; 
At The Rockef€11er University Hospital, 
Assistant Professor Robert Darnel I (center) ,, , 
confers with M.D.-Ph.D. students Ronald 
Buckanovich and. Lori Newman. 
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Z anvil A. Cohn, Henry G. Kunkel Professor and vice president for medical affairs at The Rockefeller University, died of an aortic dissection June 28. 
A leading cell biologist and immunologist at Rockefeller for thirty-five 
years, Cohn was a pioneer in the modern study of the body's defense mechanisms 
against infection. His groundbreaking experiments have shaped the modern science 
of macrophages, the large white blood cells that are pivotal in inflammation and 
immunity. Cohn was best known for elucidating mechanisms whereby these cells 
identify, engulf, and destroy infectious microbes. His laboratory also discovered 
dendritic cells and demonstrated their potency in initiating an immune response. 
Cohn was committed to supporting young scientists, and scores of men and 
women he trained have become leaders in universities throughout the world. He 
also helped establish the university's M.D.-Ph.D. program in the early 1970s, and 
his stewardship of the program continued until his death. 
A graduate of Bates College (B.S., 1948) and Harvard Medical School (M.D., 
summa cum laude, 1953), Cohn came to Rockefeller in 1958 as a research associate 
and assistant physician. He was appointed professor and senior physician in 1962, 
the first Henry G. Kunkel Professor in 1986, and vice president for medical affairs 
in 1992. From 1977 until the time of his death, Cohn was also adjunct professor of 
medicine at Cornell University Medical College. 
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"Zan was a prince of a man wh 
fortunate enough to have know 
eminent scientist, a caring phy 
human being guided by a c 
stance. His studies of inflammati 
are classics and he used his kno 
the clinic to treat infectious dis 
rosy, TB, and AIDS. A man of 
Zan reached out to colleagu 
countries around the world. He 
colleague who helped build up a 
research and clinical activiti 
The Rockefeller U nivers 
teacher, Zan was greatly admi 
by his students: you can hear 
speaking of his scientific acume 
sensitivity to their needs, his ab· 
them to become independent S�i�ii�i.��� 
a member of the university faculty for thirty-five 
years and he came to embody what this university 
stands for: Pro Bono Humani Generis."
President Torsten Wiesel 
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"Martin was renowned throughout the world in 
the field of clinical and experimental dermatol­
ogy, and he was recognized for his contribu-
__, . ..,._.u. .  ,�.., of psoriasis, epidermolysis bul­
·1 losa, skin cancer, and wound healing. He was a
superb clinician with profound insights and a
sense of�u,manity. Martin was an important
and integr;l merriber of our faculty, chairing
.l t·h.e Executive c<Jn··· mittee-during a critical peri-d in our history\He was always ready to work
r the best interests of this institution. On the 
mpus riartin, J_as l_oved and respected not 
ed clinical scientist but also 
anjd h.Js readiness to stand up for 
i .. :, < I nstdefed right. He was a generous 
,,,,,,) t iods m.:!tn who enjoyed his family, 
, and civic activities. The 
rsity had a very special place 
have lost a very dear and 
al." 
D. MARTIN CARTER 
1 9 3 6 1 9 9 3 
D Martin Carter, Carl J. Herzog Professor of Clinical Investigation and senior physician at The Rockefeller University, died Nov. 7 of a dissect­• ing aortic aneurysm. 
Renowned throughout the world in the field of clinical and experimental der­
matology, Carter made many important contributions to the scientific understanding 
of genetic and environmental factors that influence the development of diseases of 
the skin, as well as to treatments for these conditions. Carter was a pioneer in the use 
of psoralens-photosensitizing drugs-in a variety of diseases. A pioneer also in cel­
lular and molecular studies on epidermolysis bullosa, a group of rare hereditary dis­
orders, he was the founder of the National Epidermolysis Bullosa Registry. Carter 
was also a highly respected physician and distinguished teacher. 
A graduate of Dartmouth College (A.B., 1958), Harvard Medical School (M.D., 
1961), and Yale University (Ph.D., 1971), Carter came to Rockefeller in 1981 to 
head the new Laboratory for Investigative Dermatology. He was previously affiliated 
with Yale University School of Medicine. At the time of his death, Carter also served 
as professor of dermatology and co-head of the Department of Dermatology at The 
New York Hospital-Cornell Medical Center at Cornell University Medical College. 
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THE BEGINNING QF A YEAR-LONG CELEBRATION· 
50 YEARS OF DNA 
OJ 
C 
Ql 
C 
0 
I 
C 
C 
Ql ,---, 
Below, President 
To commemorate the fiftieth
·: .. anniversary of the·discovery at The R�ckefeller 
University that genes are made of DNA-con-
Torsten Wiesel 
(right) with P�ofessor 
Emeritus Maclyn 
McCarty (center), 
co-author of the 
paper with Oswald 
Avery and Colin 
MacLeod, anq j ames; 
D. Watson, direc.tor 
of Cold Spring 
Harbor Laboratory. 
sidered by many to be the single most important 
biological discovery of the twentieth century­
the university .has kicked off a year-long series 
of events that will run through May 1994. 
"The 1944 discovery of Oswald Avery, 
. Colin MacLeod, and Maclyn McCarty opened 
the gateway to the modern era of biology and 
medicine," said President Torsten Wiesel� "_In 
"'' ,,,j,\ , ,�elebrating this historical event, we cel­
ebrate as well The Rockefeller 
University's enduring mission of diag­
nosing and curing sickness by uncover­
ing the inner secrets.of life." 
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The celebration was formally inau­
gurated in November 1993 with a lec­
ture by Nobel laureate James D .: 
Watson, best known for discovering the 
, double-helical structure of DNA. 
A banner on the portico 
of The Rockefeller 
University Hospital 
proclaims, "50 Years of 
DNA: Celebrating the 
Avery Laboratory and 
the Discovery of the 
Thread of Life." 
Above, Pioneering 
microbiologist 
Oswald A very 
works in his lab, 
around 1944. 
AVERY CELEBRATION EVENT SCHEDULE 
WEDNESDAY, FEBRUARY 2, 1994 
Public Lecture 
5:00 P.M. 
"The Human Genome Project in Its Scientific Context" 
David Botstein, Stanford University School of Medicine 
THURSDAY, FEBRUARY 3, 1994 4:00 P.M. 
Historical Roundtable 
Discussion with key scientists active between the publication of 
the 1944 Avery, MacLeod, and McCarty paper and the 1953 dis­
covery of DNA's double-helical structure. 
Moderator: Robert Olby, The Rockefeller University; author 
of The Path to the Double Helix
Speakers: Erwin Chargaff, College of Physicians and 
Surgeons of Columbia University (emeritus); Seymour S. Cohen, 
SUNY at Stony Brook (emeritus); Alfre,d Day Hershey, Carnegie 
Institute (former director); Rollin Hotchkiss, The Rockefeller 
University (emeritus); Joshua Lederberg, The Rockefeller 
University; Maclyn McCarty, The Rockefeller University 
(emeritus); Norton K. Zinder, The Rockefeller University 
FRIDAY, FEBRUARY 4, 1994 
Scientific Symposium 
3:45 P.M. 
Leading scientists in research areas pursued by the Avery labora­
tory-immunology, infectious disease, and molecular medicine. 
Moderator: Emil Gotschlich, The Rockefeller University 
Speakers: Robert Austrian, School of Medicine, University of 
Pennsylvania; John B. Robbins, National Institutes of Child 
Health and Human Development, National Institutes of Health 
MONDAY, APRIL 18, 1994 6:00 P.M. 
Public Lecture on Ethics and DNA Technology 
Nancy Wexler, Columbia University 
FRIDAY, MAY 6, 1994 3:45 P.M. 
Scientific Symposium 
Panel of young scientists working in key areas of DNA research at 
The Rockefeller University 
Moderator: Jan L. Breslow, The Rockefeller University 
Speakers: To be announced. 
I 
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